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Abstract
!
Background: The prevalence and socioeconomic
burden of type 2 diabetes (T2DM) and associated
co-morbidities are rising worldwide. Aims: This
guideline provides evidence-based recommenda-
tions for preventing T2DM. Methods: A European
multidisciplinary consortium systematically re-
viewed the evidence on the effectiveness of
screening and interventions for T2DM prevention
using SIGN criteria. Results: Obesity and seden-
tary lifestyle are the main modifiable risk factors.
Age and ethnicity are non-modifiable risk factors.
Case-finding should follow a step-wise procedure
using risk questionnaires and oral glucose toler-
ance testing. Persons with impaired glucose toler-
ance and/or fasting glucose are at high-risk and
should be prioritized for intensive intervention.
Interventions supporting lifestyle changes delay
the onset of T2DM in high-risk adults (number-
needed-to-treat: 6.4 over 1.8–4.6 years). These
should be supported by inter-sectoral strategies
that create health promoting environments. Sus-
tained body weight reduction by ≥ 5% lowers risk.
Currently metformin, acarbose and orlistat can be
considered as second-line prevention options.
The population approach should use organized
measures to raise awareness and change lifestyle
with specific approaches for adolescents, minor-
ities and disadvantaged people. Interventions
promoting lifestyle changes are more effective if
they target both diet and physical activity, mobi-
lize social support, involve the planned use of es-
tablished behaviour change techniques, and pro-
vide frequent contacts. Cost-effectiveness analysis
should take a societal perspective. Conclusions:
Prevention using lifestyle modifications in high-
risk individuals is cost-effective and should be
embedded in evaluated models of care. Effective
prevention plans are predicated upon sustained
government initiatives comprising advocacy,
community support, fiscal and legislative
changes, private sector engagement and continu-
ous media communication.
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ADA: American Diabetes Association
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CHD: Coronary heart disease
CI: Confidence interval
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rative analysis Of Diagnostic crite-
ria in Europes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
S4 Guidelines
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ity
 o
f B
ed
fo
rd
sh
ire
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.DE-Plan: Diabetes in Europe-Prevention using Lifestyle,
Physical Activity and Nutritional Intervention
Plan
DESIR: Data from Epidemiological Study on the Insulin
Resistance syndrome detected diabetes in pri-
mary care
DPP: US Diabetes Prevention Program
DPS: Finnish Diabetes Prevention Study
DREAM: Diabetes REduction Assessment w/ramipril & ro-
siglitazone Medication
EASD: European Association for the Study of Diabetes
EPIC: European Prospective Investigation into Cancer
and Nutrition study
FINDRISC: FINnish Diabetes Risk Score
FPG: Fasting plasma glucose concentration
GDM: Gestational diabetes
GWAS: Genome-wide association studies
HR: Hazard ratio
IDF: International Diabetes Foundation
IDPP: Indian Diabetes Prevention Program
IFG: Impaired fasting glucose
IGLOO: Impaired Glucose tolerance and Long-term Out-
comes Observational
IGT: Impaired glucose tolerance
MetSy: Metabolic syndrome
MRF: Multiple Risk Factor Intervention Trial
NCEP‑ATP III: National Cholesterol Education Program
NGT: Normal glucose tolerance
NHANES III: Third National Health and Nutrition Examination
Survey
NNT: Number needed to treat
OGTT: Oral glucose tolerance test
OR: Odds ratio
PCOS: Polycystic ovary syndrome
PG: Plasma glucose concentration
PIPOD: Pioglitazone In Prevention of Diabetes
QALY: Quality adjusted life years
RCT: Randomized controlled trial
RIO: Rimonabant-In-Obesity
RR: Relative risk
SES: Low socioeconomic status
SMOMS: Scandinavian Multicenter on Orlistat in Metabolic
Syndrome
SOS: Swedish Obesity Surgery
STOP-NIDDM: Study To Prevent Non-Insulin-Dependent Diabe-
tes Mellitus
T2DM: Type 2 diabetes mellitus
TRIPOD: Troglitazone In Prevention of Diabetes
WHO: World Health Organisation
XENDOS: XEnical in the prevention of Diabetes in Obese
SubjectsIntroduction
!
It is estimated that the number of people with diabetes will reach
285 million people worldwide in 2010, with almost half of those
affected in the 20–60 age group. In Europe about 55 million peo-
ple aged 20–79 will have diabetes in 2010 and this number is ex-
pected to rise to 66 million by 2030 unless effective preventive
strategies are implemented. Type 2 diabetes (T2DM) accounts
for about 90% of diabetes cases. People with T2DM have a 2- toPaulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 2014-fold increased risk of cardiovascular disease (CVD) and at least
two thirds die from CVD. Increased CVD risk is already present in
prediabetic states, particularly in individuals with impaired glu-
cose tolerance (IGT) [1,2] and/or the metabolic syndrome
(MetSy) [3]. Diabetes and its complications represent an enor-
mous burden not only for patients but also for society. Direct
healthcare costs, which represent about 30% of total costs to so-
ciety, will be about 70 billion € per year in 2010. It has been esti-
mated that if an individual is diagnosed as having diabetes at the
age of 40 years, men will lose on average 11.6 life-years and 18.6
quality adjusted life years (QALY) and women will lose 14.3 life-
years and 22.0 QALYs [4]. Thus, primary prevention of T2DM and
its complications is a major public health issue.
Despite the fact that inherited factors predispose to T2DM, envi-
ronmental and lifestyle factors are held mainly responsible for
the increasing prevalence of the disease over the past decades.
There is now strong evidence from controlled trials that T2DM
can be prevented by interventions that deliver relatively modest
lifestyle changes. Thus, the potential to prevent T2DM represents
a major opportunity for European governments and healthcare
systems.
In order to address the challenge of reversing the epidemic of
T2DM, a European multidisciplinary consortium (the IMAGE
project: www.image-project.eu) developed this guideline for the
prevention of T2DM which provides evidence based recommen-
dations for health care practitioners, organizations, and funders
on the prevention of type 2 diabetes in European healthcare set-
tings.Definition of Risk and Target populations
!
Definition of risk
The risk for T2DM is predominantly determined by number and
severity of non-modifiable and modifiable risk factors (l" Table
1).
Non-modifiable risk factors
Age. Age is one of the strongest risk factors for T2DM (A). Epide-
miological data for diabetes and impaired glucose regulation
from 13 European countries have been published by the DECODE
study group [5]. The prevalence of diabetes rises with age up to
the 8th decade in both men and women. It is less than 10% in
subjects below 60 years and exceeds 20% above 80 years. The
mean plasma glucose concentration at 2 hours (2-h PG) of the
oral glucose tolerance test (OGTT) rises with age in European
populations, particularly after 50 years. Women have higher
mean 2-h PG levels than men, particularly above 70 years. Mean
fasting plasma glucose (FPG) levels increase only slightly with
age. They are higher in men than in women aged 30–69 years
and become higher in women after 70 years. Among middle aged
subjects, the prevalence of impaired glucose regulation (impaired
glucose tolerance [IGT] and impaired fasting glucose [IFG], or
both) is about 15%, whereas in the elderly, 35–40% of Europeans
have impaired glucose regulation. Over the last years, the age of
onset of diabetes has decreased considerably in countries in
which the prevalence of obesity has increased significantly [6–
10]. T2DM now accounts for as many as 50% of cases of newly di-
agnosed cases of diabetes in pediatric populations [11]. Earlier
onset of T2DM leads to earlier onset of the complications.
Markers of increased CVD risk may appear even before the diag-
nosis of the MetSy among obese children and adolescents [12]0; 42 (Suppl. 1): S3–S36
Table 1 Risk factors for T2DMNon-modifiable risk factors Modifiable risk factors
" Age " Overweight and obesity
" Family history/Genetic predisposition " Physical inactivity
" Ethnicity " Disturbances in intrauterine development/prematurity
" History of gestational diabetes (GDM) " Impaired fasting glucose (IFG)/Impaired glucose tolerance (IGT)
" Polycystic ovary syndrome (PCOS) " Metabolic syndrome (MetSy)
" Dietary factors
" Diabetogenic drugs
" Depression
" Obesigenic/diabetogenic environment
" Low socio-economic status
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l.and metabolic abnormalities diagnosed in the adolescence tend
to persist into adulthood [13].
Family history/genetic predisposition. Occurrence of the dis-
ease is highly concordant (60–90%) in monozygotic twin pairs,
but less so (17–37%) in dizygotic twins [14–17] (A). The child of
a parent with T2DM has a 40% chance of developing the disease,
whereas the risk in the general population is about 7% [18]. In the
Botnia study, a positive family history with at least one affected
first degree relative was associated with a hazard ratio (HR) of
2.2 for development of the disease [19]. In recent years a large
number of genetic variants have been identified, which increase
the risk for T2DM [20]. Genome-wide association studies pro-
vided by far the biggest increment to our knowledge of the genet-
ics of T2DM [21–26]. At least 25 gene loci have been identified so
far affecting susceptibility for T2DM [27] (A). The effect on T2DM
risk per susceptibility allele ranges from about 10% to 40%. The
majority of these genes appear to play a role in beta-cell function
rather than in insulin sensitivity. Collectively, however, these var-
iants explain less than 10% of the genetic component of diabetes
risk. Therefore despite the encouraging progress in our under-
standing of the genetic basis of T2DM, it is too early to use genetic
information as a tool for targeting preventive efforts [19].
Ethnicity. Studies in multiethnic populations suggest that some
ethnic groups have a particular predisposition, most likely on a
genetic basis, to develop insulin resistance and T2DM, when ex-
posed to adverse conditions [20]. There are wide differences in
the prevalence of diabetes between ethnic groups (A) [28]. The
prevalence of diagnosed diabetes among Hispanics is 1.9 times
higher than that among Caucasians. Diabetes is diagnosed at an
earlier age and Hispanics suffer from higher rates of diabetes-re-
lated complications and mortality [29]. Afro-Caribbeans and
Asian Indians also exhibit higher prevalence of T2DM than Cau-
casians [30]. One important factor contributing to increased
T2DM risk in Asian Indians is the greater insulin resistance com-
pared to Caucasians [31].
Gestational diabetes (GDM). GDM is defined in terms of having
glucose intolerance in the diabetic range as assessed from OGTT
and/or FPG that begins or is first diagnosed during pregnancy
[32,33]. It is estimated to affect between 3 and 5% of all pregnan-
cies [32] There is a strong correlation between a history of GDM
and later development of T2DM and its co-morbidities [34]. A re-
cent meta-analysis of 20 studies reported that womenwith a his-
tory of GDM had about a 7.5-fold increased risk for T2DM com-
pared with womenwith normoglycemic pregnancy [35] (A). Eth-
nicity has been proven to be an independent risk factor for GDM
[36]. In the DPP women with a history of GDM randomized toPaulweber B et al. IMAGE-Gplacebo had an incidence rate of T2DM about 70% higher than
that of women without such a history, despite equivalent levels
of glucose intolerance at baseline [37]. Metabolic assessments
recommended after GDM are [33,38] (D): post delivery (1–3
days): FPG or random PG to detect persistent or overt diabetes,
6–12 weeks postpartum: OGTT, 1 year postpartum: OGTT, annu-
ally: fasting plasma glucose, tri-annually and pre-pregnancy:
OGTT to classify glucose metabolism.
Polycystic ovary syndrome (PCOS). PCOS affects about one in 15
womenworldwide with up to 10% of women of reproductive age
[39] and shows familial aggregation and ethnic variation in its
prevalence. At present, there are three main definitions for PCOS.
The National Institutes of Health (NIH) criteria require the pres-
ence of hyperandrogenism and/or hyperandrogenemia, chronic
anovulation, and exclusion of related disorders such as hyperpro-
lactinemia, thyroid disorders, and congenital adrenal hyperplasia
[40]. The 2003 Rotterdam criteria include two or more of the fol-
lowing in addition to exclusion of related disorders: oligo-anovu-
lation or anovulation, clinical and/or biochemical signs of hyper-
androgenism, polycystic ovaries [41]. The most recent criteria
was defined by a task force of the Androgen Excess Society (AES)
in 2006, which recommended the following criteria: hirsutism
and/or hyperandrogenemia, oligo-ovulation and/or polycystic
ovaries, exclusion of other androgen excess or related disorders
[42]. Using the NIH criteria in unselected populations of women
of the reproductive age the prevalence of PCOS is 6.5–8.0% [43].
The 2003 Rotterdam criteria result in a 1.5 fold higher prevalence
of PCOS [44].
The etiology of PCOS is incompletely understood, but studies sug-
gest a strong genetic component influenced by gestational envi-
ronment and lifestyle factors. Most women with PCOS have in-
creased insulin resistance and impaired β-cell function compared
with age- and BMI-matched controls [45]. Approximately 30% of
women with PCOS have IGT and up to 10% are diabetic [46]. In
the United States up to 40% of all women with PCOS have devel-
oped T2DM or IGT by the age of 40 years [47]. More pronounced
endocrine disturbances conferring a particularly high risk for
T2DM are observed in women with PCOS and obesity as com-
pared with normal weight women with this condition [48].
Women with PCOS have a higher incidence of GDM, pregnancy-
induced hypertension, and preeclampsia [49]. A recent meta-
analysis revealed an approximately 3-fold increased risk as as-
sessed from the odds ratio of 2.94 [95% confidence interval, CI
1.70, 5.08] for GDM among women with PCOS [50].
Modifiable risk factors
Overweight and obesity. Obesity (BMI ≥ 30 kg/m2) and over-
weight (BMI 25–30 kg/m2) increase the risk for developing bothuideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 2 Classification of glucose homeostasis based on fasting blood glucose and 2-hour blood glucose after a 75-g oral glucose tolerance test (OGTT)
Fasting glucose Venous plasma (mmol/l/mg/dl) Capillary whole blood (mmol/l/mg/dl)
Normal fasting glucose < 6.1/<110 < 5.6/<100
Impaired fasting glucose 6.1 and < 7.0/110 and < 126** 5.6 and < 6.1/100 and < 110
Diabetes 7.0/126 6.1/110
2 h glucose*
Normal glucose tolerance < 7.8/140 < 7.8/140
Impaired glucose tolerance 7.8 and < 11.1/140 and < 200 7.8 and < 11.1/140 and < 200
11.1/200 11.1/200
*Glucose level 2 h after ingestion of 75 g oral glucose load; if 2 h glucose is not measured, status remains uncertain as diabetes or IGT cannot be excluded; ** according to the
classification recommended by the ADA impaired fasting glucose is defined as fasting plasma glucose levels between 5.6 and 7.0mmol/l (100–126mg/dl)
S6 Guidelines
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l.IGT and T2DM at all ages [51]. They act, at least in part, by induc-
ing insulin resistance [52]. More than 80% of cases of T2DM can
be attributed to obesity. Reversal of obesity also decreases the
risk for T2DM (A) [53] and improves glycemic control in patients
with established diabetes (A) [54]. A strong curvilinear relation-
ship between BMI and the risk for T2DM was found in women in
the Nursesʼ Health Study (B) [55]. The age-adjusted relative risk
for diabetes was 6.1 times higher for people with BMI >35 kg/m2
than for people with BMI < 22 kg/m2. The degree of insulin resis-
tance and the incidence of T2DM are highest in those subjects
with upper body or abdominal adiposity, as assessed from waist
circumference [56,57]. Adiposity of the “gynoid" type, which pri-
marily affects the gluteal and femoral region is not associated
with glucose intolerance or increased CVD risk. However, studies
trying to discern the relative importance of waist circumference
(or waist-to-hip ratio) compared to BMI regarding risk for T2DM
development have not shown a major advantage of one over the
other (A) [58].
Physical inactivity. Recent data from the Nurses Health Study in-
dicate that both obesity and physical inactivity independently
contribute to the development of T2DM: the magnitude of risk
contributed by obesity, seems to be greater than that imparted
by lack of physical activity [59,60]. The benefit of physical activ-
ity in preventing diabetes has been demonstrated in several stud-
ies (A) [61–69].
Disturbances in intrauterine development/prematurity. There
is an inverse association between birth weight and risk for
T2DM. Specifically, subjects who had a low birth weight for ges-
tational age have, as adults, reduced β-cell function [70], insulin
resistance [71] and an increased incidence of T2DM (B) [72].
Small-for-gestational-age babies are those whose birth weights
lie below the 10th percentile for their gestational age. Low birth
weight (< 2500 g) is sometimes used synonymously. Thinness at
birth and in adult life have opposing effects on insulin resistance,
such that subjects who were underweight at birth, but who be-
come overweight in middle age, have the most severe insulin re-
sistance and the greatest risk for T2DM [73]. Higher birth weight
(> 4000 g) may also be associatedwith an increased risk for T2DM
(B) [74]. Large-for-gestational-age babies are those whose birth
weights lie above the 90th percentile for their gestational age. A
meta-analysis of 14 studies demonstrated a U-shaped relation-
ship between birth weight and diabetes risk [75]. Both high and
low birth weight were similarly associatedwith increased risk for
diabetes later in life (OR: 1.36 and 1.47). Children born prema-
turely, whatever their weight, may also be at increased risk for
T2DM (B) [76,77].Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201Impaired fasting glucose (IFG) and impaired glucose tolerance
(IGT). IFG and IGT are early abnormalities of glucose metabolism
that precede diabetes. These are often called prediabetes. IFG is
defined as an elevated FPG concentration between 6.1–
6.9mmol/l. In 2003 the lower cut-off value was reduced to
5.6mmol/l by the American Diabetes Association (ADA) [78],
which was not accepted by the WHO in 2006 [79] (l" Table 2).
IGT is defined as an elevated PG between 7.8 and 11.1mmol/l at
2 hours after a 75-g OGTT, in the presence of an FPG < 7mmol/l
[78,80]. It is clear that with the definitions above, there is overlap
between the two groups. Thus, additional groups have been cre-
ated, namely isolated IFG (i-IFG), isolated IGT (i-IGT) and IFG plus
IGT (IFG + IGT).
The prevalence of IFG and IGT varies considerably among differ-
ent ethnic groups and increases with age (B). IGT is more com-
mon in women. IFG and IGT are believed to represent different
metabolic abnormalities. The reported estimates of diabetes de-
velopment in IFG and IGT individuals vary widely, depending on
the ethnicity of the population studied, with a higher incidence
of T2DM noted in non-Caucasian populations (B).
Two recent meta-analyses found no evidence of a difference in
T2DM risk among people with either IGT, IFG, i-IGT or i-IFG
[81,82], but both concluded that individuals with IFG + IGT have
a substantially increased risk of T2DM compared to all other
groups (B). The first meta-analysis included 44 studies and calcu-
lated the unadjusted annualized relative risk (RR) for progression
to diabetes at 6.02 for IGT, 5.55 for IFG and 12.21 for IFG + IGT. The
second meta-analysis included 40 studies and the RR was found
to be 6.35 for IGT, 4.66 for IFG and 12.13 for IFG + IGT. Of note,
most of the literature on IFG is based upon the older cut-off point
(6.1–6.9mmol/l) while the risk associated with IFG as more re-
cently defined by the ADA (5.6–6.9mmol/l) in 2003 remains to
be evaluated.
According to the available data, it has been estimated that the
majority of individuals (probably up to 70%) with these predia-
betic conditions will eventually develop diabetes [83]. However,
studies of shorter duration have shown that during a period of
3–5 years about 25% of individuals progress to diabetes, 25% re-
turn to a normal glucose tolerance status and 50% remain in the
prediabetic state (B) [84,85].
Metabolic syndrome (MetSy). MetSy is defined as a cluster of
metabolic risk factors for cardiovascular diseasewhich are associ-
ated with insulin resistance [86,87]. It is associated with an up to
2-fold elevated risk for CVD [3]. Although several diagnostic crite-
ria have been proposed by different organizations, there is an on-
going debate regarding the existence of unique underlying path-
ophysiology [88–90]. The most widely used criteria were defined0; 42 (Suppl. 1): S3–S36
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l.by the National Cholesterol Education Program (NCEP‑ATP III)
and include central obesity, high fasting plasma glucose, high tri-
glycerides, low HDL-cholesterol and high blood pressure [86]. A
harmonized definition of the MetSy has recently been suggested
in a joint statement issued by several international organizations
[91]. Despite the fact that the MetSy strongly predicts progres-
sion to T2DM [92], several reports [93–95] show that a single
measure of blood glucose is a better predictor of incident diabe-
tes than the complex definition of the MetSy. In a recent analysis
from the San Antonio heart study, however, the metabolic syn-
drome as defined by the NCEP criteria predicted T2DM indepen-
dently of the presence of elevated FPG [96]. The MetSy was as
good a predictor for the occurrence of T2DM as iIFG (OR: 5.03
versus 7.07). If both conditions occurred simultaneously, the risk
for T2DM was much higher (OR: 21.0).
Dietary factors. Diet is thought to play an important role, and
some data suggest that certain dietary factors may predict
T2DM but confounding factors limit many nutritional clinical
studies. Even randomized nutritional clinical trials often suffer
from several short-comings as they may start too late in the dis-
ease process, not be continued for sufficient duration or be inad-
equately powered. In addition, the protective (or deleterious) ef-
fect of a certain nutrient may only operate in conjunction with
other nutrients or at a particular intake level. Finally, poor dietary
compliance is another common problem of dietary trials. It is
clear however that diet can influence the development of T2DM
by affecting bodyweight. It has been shown that a dietary pattern
promoting weight loss reduces the risk of T2DM (A) [61,65,68].
More recently, higher T2DM risk was also found to be associated
with diet composition, particularly with low fibre intake.
Low fibre intake [97–100]. Individuals with low intake of dietary
fibre, particularly of insoluble cereal fibre, have been found to be
at increased risk for T2DM in several epidemiologic studies (B)
[101,102]. In studies aimed at diabetes prevention by lifestyle
modification, an increase in fibre consumption was often part of
the intervention [61,65]. Fibre has a low glycemic index, which
may contribute to T2DM risk reduction. However, the evidence
for an increased risk associated with high glycemic index and
high glycemic load diets is mixed [98–100,103]. Nevertheless, a
recent meta-analysis of 37 prospective cohort studies (B)
showed, in fully adjusted models, that both high glycemic load
(RR 1.27 [95% CI 1.12, 1.45]) and high glycemic index (RR 1.40,
[95% CI 1.23, 1.59]) diets are associated with increased risk for
T2DM [104]. It must be emphasized that fibre rich foods gener-
ally have a low GI, although not all foods with a low GI necessarily
have high fibre content.
Low unsaturated/saturated fat ratio [105–107]. Shifting from a
diet based on animal fat to a diet rich in vegetable fat might re-
duce the risk for T2DM (B) [61,65]. An increased intake of
monounsaturated fat appears to be of particular benefit (C)
[108]. Recent studies revealed a weak positive correlation be-
tween intake of long chain omega-3 fatty acids (LCFA) and diabe-
tes risk [109,110].The beneficial effects of LCFA on other health
outcomes, however, are well established [108,111]. The con-
sumption of trans fatty acids has consistently been found to be
associated with increased risk for T2DM [112] and CVD [113] (A).
Other nutrients. A less consistent but still significant body of evi-
dence suggests that the risk for T2DM is lowered by regular con-Paulweber B et al. IMAGE-Gsumption of moderate amounts of alcohol (B) [114,115], fruits
and vegetables (B) [116], nuts (B) [117] and coffee (B) [118]. It
must be emphasized that people do not consume nutrients in
isolation but rather ingest a variety of nutrients at the same time
as they eat their food [119]. The study of different dietary pat-
terns such as the “Mediterranean diet” is an alternative approach
to examining the possible relationships between diet and T2DM
[120].
Diabetogenic drugs. A large number of drugs mayworsen in gly-
cemic control in diabetic patients, or even cause diabetes in pre-
disposed people. These drugs include various classes of agents
[121], such as glucocorticoids, antihypertensive drugs (beta
blockers, thiazide diuretics) [122], niacin, immunosuppressive
drugs, gonadotropin releasing hormone agonists, pentamidine,
diazoxide, atypical antipsychotic agents [123], the antineoplastic
agent asparaginase, danazole, and anti-retroviral drugs used for
the treatment of HIV infection [124].
Obesogenic/diabetogenic environment. The recent increase in
T2DM seems to be strongly linked to unfavorable changes in the
environment (B) [125]. The abundant availability of energy dense
and highly palatable food and changes in transport, work and lei-
sure infrastructure and opportunities decreasing physical activ-
ity are the main obesogenic and diabetogenic environmental fac-
tors [126]. To change this environment in a beneficial way is a
major challenge for T2DM prevention [127,128].
Smoking increases the risk for T2DM by adversely affecting insu-
lin sensitivity and beta-cell function [129,130]. The potential of
xenobiotics to disturb glucose and lipid metabolism in mammals
is well established [131].
A strong correlation between insulin resistance and serum con-
centrations of persistent organic pollutants (POPs), especially or-
ganochlorine compounds has been reported [131–136]. It has al-
so been proposed that modern food processing can generate dia-
betogenic compounds, such as glycation end products or oxidized
ascorbic acid and lipoic acid [125].
Depression. Psychosocial factors may play a causal role in the
chain of events leading to development of the MetSy [137]. De-
pression has been considered as a risk factor for T2DM and its
complications [138,139] and an increased risk for developing
T2DM in adults with depression has been demonstrated in a
meta-analysis of 9 longitudinal studies [140] (B). A recent analy-
sis of the DPP found that baseline antidepressant use was associ-
atedwith diabetes risk in the placebo and intensive lifestyle arms,
but not in the metformin arm [141]. Potential mediators of the
effects of depression on diabetes risk have been summarized
elsewhere [139].
Low socio-economic status. Several studies have recognized the
adverse influence of low socioeconomic status (SES) on general
health, prevalence of obesity, smoking, CVD, and early mortality
[142–148]. There is also an inverse association between SES and
T2DM, with a higher prevalence among less-advantaged groups.
This appears to be consistent across several developed countries
and across different ethnic groups (B) [149–157]. An inverse
graded association between diabetes prevalence, metabolic dis-
orders and different measures of SES such as education, occupa-
tion, income, poverty income ratio, and measures of material
deprivation and poverty has been found (B) [158–162]. Although
T2DM prevalence is increasing in the population at large, the in-uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
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In some, but not all studies an independent association between
lower SES in childhood and increased risk for T2DM and cardio-
vascular disease in adulthood has been observed [163–168]. The
underlying processes are not yet fully understood, but associa-
tions between lower SES and diabetes risk factors like obesity,
waist circumference, smoking, inappropriate diet, and leisure
time inactivity appear to be important [169–171].
Definition of target populations
For successful prevention of T2DM both a whole population ap-
proach and an individual (targeted high-risk) approach are rec-
ommended.
Whole population approach
The IDF consensus [172] recommends a population as well as an
individually targeted approach for diabetes prevention. Simply
distributing information about T2DM risk and available strat-
egies for risk reduction, however, is not sufficient to reverse the
T2DM epidemic. For successful prevention it is important to cre-
ate environmental conditions that are conducive to achieving and
maintaining a healthy lifestyle. The health sector on its own can-
not accomplish such population-wide changes. National diabetes
prevention plans are required, which should include the compo-
nents proposed in the IDF consensus, namely advocacy, com-
munity support, fiscal and legislative measures, engagement of
the private sector, media communication, and improving level of
knowledge and motivation of the population [172].
Unlike interventions that focus on high-risk individuals, the pop-
ulation approach is not supported by a large database of clinical
studies. A UK cohort study found that diabetes incidence was in-
versely related to the achievement of five “healthy behaviour
goals for diabetes prevention” (BMI < 25 kg/m2, fat intake < 30%
of energy intake, saturated fat intake < 10% of energy intake, fibre
intake ≥ 15 g/4, 184 kJ, physical activity > 4 h/week) [173]. The in-
cidence of T2DMwas inversely and linearly related to the number
of goals achieved. None of the participants who met all five goals
developed diabetes, whereas the highest incidence was observed
in subjects who did not meet any of the goals. (2++, B).
High-risk approach
It is current practice in several countries (e.g. UK, USA, Finland
and France) to recommend targeted or opportunistic screening
to identify high risk individuals. The IDF consensus document
[172] recommends the use of opportunistic screening by health
care personnel, particularly those working in primary care. Risk
for T2DM and CVDmay be assessed quantitatively by appropriate
methods such as blood testing (fasting plasma glucose, OGTT, lip-
id profile, and HbA1c) and searching for the presence of other risk
factors like family history of premature CVD, hypertension, vis-
ceral obesity, physical inactivity, unhealthy diet and smoking.
Appropriate interventions (e.g. antihypertensive and lipid ther-
apy, aspirin, smoking cessation, dietary changes, exercise, weight
loss) targeting all identified risk factors should subsequently be
initiated.
The IDF recommends the following criteria for opportunistic
screening (or targeted screening) [172]: obesity (including vis-
ceral), family history of diabetes, age, history of raised blood pres-
sure and/or heart disease, history of GDM, and drug history. Re-
cently best practice guidelines for vascular risk assessment and
management have been issued by the UK National Health Service
(www.dh.gov.uk/publications). According to these guidelines tar-Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201geted screening for T2DM risk by measuring either FPG or HbA1c
is recommended in asymptomatic subjects aged 40–74 years
with obesity and/or elevated blood pressure (≥ 140/90mmHg).
In subjects with FPG (6–7mmol/l) or HbA1c (6–6.5%) in the pre-
diabetic range, an OGTT is recommended.
Target populations for interventions
It is thought that most patients pass through a prediabetic phase
before developing T2DM [174]. Subjects with IGT are at highest
risk for T2DM, but individuals with isolated IFG and the MetSy
[95,96,175] are also at increased risk [96,176]. Particularly high
conversion rates (> 10% per year) have been observed in subjects
with a combination of 2 or 3 prediabetic conditions (IGT ± IFG,
±MetSy) [83,96]. Therefore a hierarchical approach is proposed
starting with subjects with IGT ± IFG, ±MetSy (A), IFG and/or
MetSy (C), (overweight, obesity, hypertension, or physical inac-
tivity) (C) and finally the general population (C) [177,178] (l" Ta-
ble 6). It has to be emphasized that the major prevention trials
[120] have all focused on patients with IGT (± IFG). Given the fact
that resources are limited, the intensity of the intervention
should be adjusted to the level of risk, implying that subjects at
highest risk should receive the most intensive intervention (B).
Recommendations
A hierarchical approach for prevention of T2DM is proposed:
A starting with subjects at highest risk for T2DM (IGT ± IFG,
±MetSy) with highest priority,
C followed by subjects at high risk (IFG and/or MetSy) with high
priority,
C subjects with overweight, obesity, hypertension, or physical
inactivity with medium priority and
C finally the general population with low priority.
B Given the fact that resources are limited, the intensity of the
intervention should be adjusted to the level of risk, implying that
subjects at highest risk should receive the most intensive inter-
vention.Screening Tools, Diagnosis and Detection
!
Categorization of abnormal glucose metabolism
In practice, the glucometabolic category depends on whether
FPG is measured alone or combined with a 2-h PG. For example
an individual falling into the IFG category may also have IGT or
diabetes, which would only be discovered by a post-load BGmea-
surement. In the text, IFG and/or IGTwill be defined as prediabe-
tes. As to HbA1c, a high HbA1c level may only identify a fraction
of asymptomatic people with diabetes. HbA1c is insensitive in
the low range and a normal HbA1c level cannot exclude the pres-
ence of diabetes or prediabetes.
Epidemiological arguments
Several epidemiological studies have challenged the practice of
not using the 2-h PG and have showed that a substantial number
of people who do not meet the FPG criteria for glucose disorders
will satisfy the criteria when exposed to an OGTT [180–182].
Thus, the OGTT is more sensitive than FPG for detecting diabetes
and the only way to detect IGT. The probability of false negative
results is substantial, when measuring FPG only. But there are
some important arguments against OGTT. OGTT needs to be per-
formed in appropriate conditions and should be standardized
(Appendix 1). In particular, OGTT should be carried out after at0; 42 (Suppl. 1): S3–S36
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This test has been considered to be less appropriate at a popula-
tion level, mainly because it takes more than 2 h to perform, is
costly and has a low reproducibility. However, the true primary
prevention of diabetes requires the identification of high-risk
subjects and treatment to prevent their transition to overt diabe-
tes. This needs a definite categorization of glycemic states.
Arguments based on the natural history of glucose
abnormalities
The rate of conversion to diabetes is very high in people with IGT
or IFG, and even higher in those with IGT + IFG, as discussed ear-
lier. Approximately 30% of people with IGTwill convert to T2DM
within 5 years [183] implying that at-risk individuals should be
screened for both IFG and IGT.
Arguments based on prevention trials
To date, prevention trials mainly included patients with IGT,
whereas only one trial included also patients with IFG only [61,
65,68,184–187]. This trial showed that prevention of the transi-
tion from IFG to diabetes is possible so that IFG may also be con-
sidered a target for intervention [188].
Arguments based on CVD risk
Patients with IGT are at high risk for developing CVD. The most
convincing evidence of increased CVD risk was provided by the
DECODE (Diabetes Epidemiology: Collaborative analysis Of Diag-
nostic criteria in Europe) study, which showed that IGT is more
predictive of CVDmortality than FPG levels [5]. Many individuals
with prediabetes have a cluster of other cardiovascular risk fac-
tors, i.e. abdominal adiposity, elevated triglycerides, low HDL-
cholesterol, elevated blood pressure, known as components of
the MetSy, as well as raised LDL-cholesterol levels [189].
Taking all of the above arguments into account, it is strongly sug-
gested that clinicians categorize the type of glycemic abnormal-
ities as precisely as possible to identify people with IFG and IGT
and, in those with IGT, to screen for associated CVD risk factors,
in order to achieve the goals of both diabetes and CVD preven-
tion. However this step should be preceded by a screening phase
in order to select subjects with a high chance of having prediabe-
tes or developing T2DM.
Detection of people at high risk for diabetes
Detection programmes may be targeted widely or restricted to
higher risk populations. They may use risk scores and/or blood
glucose measurement. Scoring systems based on the presence
and extent of a number of aetiological factors may be helpful to
identify people at high risk for T2DM. They need to be reliable,
simple and practical. A number of tools have been developed to
screen for undiagnosed diabetes and/or diabetes and for the risk
of incident diabetes (l" Tables 3, 4).
Several risk scores based on large cohort studies are available
[85,190–196]. However, fewof these rely on factors that aremea-
surable with non-invasive methods and are not therefore appli-
cable outside of clinical practice. Most were developed to rate
the risk for developing T2DM (l" Table 4) and some seem to be
valuable for detecting current undiagnosed diabetes (l" Table 3),
and for identification of patients with MetSy, insulin resistance
and at risk for CVD. Therefore such questionnaires are able to se-
lect populations in whom blood glucose could be measured and/
or lifestyle advice provided in order to prevent diabetes. Some
scores directly require a diagnostic test, such as random capillaryPaulweber B et al. IMAGE-Gglucose measurement (interpreted according to time since last
meal) [197].
European population
The Finnish risk test (FINDRISC) takes only a couple of minutes,
can be taken online (www.diabetes.fi or http://care.diabetesjour-
nals.org for an English version) and provides a measure of the
probability of developing T2DM over the following 10 years. The
FINDRISC test is based on a representative random sample of the
Finnish population, aged 35–64 years and their 10-year incidence
of drug-treated T2DM. It includes 8 items: age, BMI, waist cir-
cumference, antihypertensive medication, history of elevated
blood glucose (including GDM), meeting the criterion for daily
physical activity and daily intake of fruit or vegetables. The last 2
variables were introduced to increase awareness about the im-
portance of lifestyle modifications, although they were not asso-
ciated with increased diabetes risk. The performance of this scor-
ing test as a screening tool was assessed in a cross-sectional, pop-
ulation-based survey of subjects aged 45–74 years. The risk score
was associatedwith the presence of previously undiagnosed T2D,
IGT, MetSy and CVD risk factors. Using a cut-off score of 11 (max-
imum: 20), the sensitivity to identify undiagnosed diabetes was
66% in men and 70% in women, with false-negative rates of 31%
and 39% [198]. The performance was also satisfactory in an Ital-
ian cohort [122].
A simplified version of the FINDRISC consisting of 6 questions
was validated in a German population aged 41–79 years with a
family history of T2D, obesity, or dyslipoproteinemia and found
to be a simple tool with high performance to predict diabetes risk
but less efficient to identify asymptomatic T2DM [199]. In the
IGLOO (Impaired Glucose tolerance and Long-termOutcomes Ob-
servational) study in an Italian cohort aged 55–75 years with one
or more CVD risk factors, the FINDRISC score had a sensitivity of
77% and a specificity of 45% to detect people with T2DM [122].
A Danish diabetes risk score including six questions (age, sex,
BMI, family history of diabetes, known hypertension, physical ac-
tivity at leisure time) has been developed in a population-based
sample of individuals aged 30–60 years who underwent an
OGTT. This simple score which can be completed at home identi-
fied 76% of individuals with previously undiagnosed T2DM, with
a specificity of 72%, reducing the proportion of individuals in the
population that need subsequent testing to 29% [200].
The Cambridge risk score comprises data routinely available in
UK general practice (age, sex, BMI, family history of diabetes,
smoking habits, and prescribed anti-hypertensive drugs or ste-
roids) [201] and allows to identify individuals with undiagnosed
diabetes in different ethnic groups [202–204]. It has also been
validated in a Danish population where a risk score above the
threshold of 0.246 provided a sensitivity of 71%, a specificity of
81%, and a positive predictive value of 8% to detect diabetes
[205]. The QDS score has been developed from data of 2540753
patients aged 25–79 years collected by 355 GPs in UK and Wales,
of whom 78081 had an incident diagnosis of type 2 diabetes. This
score includes ethnicity, age, sex, BMI, smoking status, family his-
tory of diabetes, Townsend deprivation score, treated hyperten-
sion, cardiovascular disease, and current use of corticosteroids.
It can be applied systematically to computerised patient data-
bases [196].
A questionnaire including readily available information (age, sex,
presence of obesity, use of anti-hypertensive medication) has
been developed from a sample of participants aged 55–75 years
who were recruited in the Rotterdam Study, to screen for preva-uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
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l.lent T2DM. This simple questionnaire has been tested in the
Dutch Hoorn Study and provides good performance at the cut-
off point of > 6 with a sensitivity 78%, specificity 55%, negative
predictive value 98%, positive predictive value 8% [206].
The German Diabetes Risk Score which includes information on
age, waist circumference, height, history of hypertension, physi-
cal activity, smoking, and consumption of red meat, whole-grain
bread, coffee, and alcohol is also publicly available (http://www.
dife.de). This score has been developed in the prospective Pots-
dam cohort of the EPIC (European Prospective Investigation into
Cancer and Nutrition) study of individuals aged 35–65 years. It
was further shown to be an accurate tool to identify individuals
at high risk for undiagnosed T2DM and to correlate well with
measures of insulin resistance and impaired insulin secretion in
three other German cohorts [207].
The Data from Epidemiological Study on the Insulin Resistance
syndrome (DESIR) study produced a risk score from a French co-
hort followed up over 9 years, and validated in two other French
cohorts [208]. It includes waist circumference and hypertension
in both sexes, and smoking in men and family history of diabetes
in women. A risk score of 5 confers a > 30% chance of diabetes in
the following 9 years.
In conclusion, the FINDRISC score meets the requirements of
being a simple, non-invasive and inexpensive tool. It has been
used in several European cohorts, and shown to be a reliable tool
both for detecting undiagnosed diabetes and for predicting fu-
ture diabetes risk. The DESIR score also meets the same criteria
but has not been tested for detecting undiagnosed diabetes. It is
simpler than the FINDRISC score, but that latter provides more
opportunities for lifestyle discussion and has been validated in
several European populations.
US population
The ADA risk test is a simple, user-friendly risk test based on age,
weight, family history of diabetes, and for women, having a baby
weighing more than 9 pounds at birth (www.diabetes.org).
The score, derived from the San Antonio Heart Study, includes
age, sex, ethnicity, BMI, family history of diabetes and systolic
blood pressure, and two biological parameters (FPG and HDL-
cholesterol) but does not perform better than FPG alone [85].
The ARIC risk score demonstrated low validity in the testing sam-
ple [100]. Furthermore its applicability to European Caucasian
populations may be limited because it was derived from a US
population.
The Diabetes Risk Calculator has been developed as a screening
tool for undiagnosed diabetes and prediabetes, based on the
Third National Health and Nutrition Examination Survey
(NHANES III) dataset (7092 participants ≥ 20 years with FPG
being measured in all at fasting, and an OGTT being performed
in approximately half of those aged 40–75 years). This tool in-
cludes simple questions and performed well [209].
Asian population
An Indian Diabetes Risk Score has been developed from the Chen-
nai Urban Rural Epidemiological Study (CURES) in India for
screening for undiagnosed diabetes. This simple test uses four
risk factors (age, waist circumference, family history of diabetes
and physical activity), and has a sensitivity of 72% and a specific-
ity of 60% with a positive predictive value of 17% and a negative
predictive value of 95% [210].Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201A simple risk equation (including age, BMI, and hypertension) has
been described in a high-risk Thai population and allowed to de-
tect 87% of undiagnosed diabetes [211].
Applicability of screening tools
Screening tests using questionnaires also need to be performed
in appropriate conditions. The FINDRISC score may be used as a
self-administered test (as it was in the first validation study).
However it is recommended that the answers should be checked
by a nurse or a physician.
More importantly, four published screening tests (Rotterdam
Diabetes Study, Cambridge Risk score, San Antonio Heart Study
and FINDRISC score) have been applied to detect undiagnosed
diabetes in a German population (KORA Survey 2000). These
tests yielded low validity when applied to that new population,
most likely due to differences in population characteristics
[212]. Low performances were also demonstrated in German
subjects with a family history of T2DM [199] and in the popula-
tion of Oman [213]. This suggests that performance of diabetes
risk questionnaires or scores must be assessed in the target pop-
ulation where they will be ultimately applied. However, all these
screening tools had a high negative predictive value (94–98%),
and thus may be helpful when the findings are negative rather
than positive.
The DETECT-2 project, an international data pooling collabora-
tion, on screening for T2D specifically addressed ethnicity and
population differences [214]. Nine datasets were selected, which
were representative of people from a diverse range of ethnic
backgrounds. The use of the Rotterdam Predictive Model [206],
yielded awide variation of the performancewith sensitivity, spe-
cificity, and percentage needing further testing ranging between
12 and 57%, 72 and 93%, and 2 and 25%, with a worse perfor-
mance in non-Caucasian populations. Thus, a risk score devel-
oped in Caucasian populations cannot be applied to other popu-
lations of more diverse ethnic origins.
After scoring for diabetes risk, it is mandatory to inform patients
about their elevated risk and to take time to deliver explanations,
in particular to low educated individuals, as recently stressed in a
study carried out in the US that included a large number of mi-
nority populations [215]. This needs to be done appropriately in
order to raise the awareness and understanding of T2DM and its
risk factors, while avoiding or minimizing negative effects, such
as emotional distress and denial [216].
Strategies for detection of people at high risk for
diabetes
Community based strategies
Various approaches exist: (i) measuring PG in specified popula-
tion groups (e.g. age over 40) to determine prevalent prediabetes
(a strategy that will detect undiagnosed diabetes as well); (ii) us-
ing computer database searches/risk-scoring algorithms or col-
lecting questionnaires to provide an estimate of the risk for inci-
dent diabetes (a strategy that leaves the current glycemic state
undetermined); (iii) using risk scores or questionnaires as pri-
mary screening tools to identify sub-groups of the population in
whom glycemic testing may be targeted efficiently.
Alternative (iii) has been tested in the IGLOO study [122]. In that
study, the use of the FINDRISC score as initial instrument, fol-
lowed by the measurement of FPG in individuals with a score ≥ 9
and by the OGTT in individuals with FPG between 5.6 and
6.9mmol/l, would have led to the identification of 83% of T2DM
cases and 57% of IGT cases, at a cost of an OGTT in 38% of the sam-0; 42 (Suppl. 1): S3–S36
Fig. 1 Community based strategies for detection
of people at high risk for type 2 diabetes.
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may be proposed, consisting of using first a risk score, then mea-
suring fasting BG, and if FPG is increased, lastly performing an
OGTT. An alternative may be performing an OGTT in all individu-
als with a high test score.
A similar approach was tested in the Anglo-Danish-Dutch study
of intensive treatment in people with screen-detected diabetes
in primary care (ADDITION [183]). Stepwise screening strategies
were performed using risk questionnaires and routine clinical
practice data plus random blood glucose, HbA1c and fasting
blood glucose measurement. Diabetes was diagnosed using the
1999WHO criteria and estimated 10-year coronary heart disease
risk was calculated using the UK Prospective Diabetes Study risk
engine. Out of 76308 people aged 40–69 years, a total of 3057 in-
dividuals with screen-detected diabetes were identified.
A community-based strategy (l" Fig. 1) should consist of a screen-
ing test as a first step in order to estimate the risk for current dia-
betes or prediabetes and the risk for future diabetes (A). In agree-
ment with the IDF, we recommend the use of opportunistic
screening by health-care personnel including those working in
general practice, nurses and pharmacists [172] (A). Self-adminis-Criteria for screening for diabetes and prediabetes within targeted populat
a)White people agedover 40 years or people fromBlack, Asian andminority ethnic g
the following risk factors:
" a first degree family history of diabetes and/or
" BMI over 25 kg/m2 and/or
" waistmeasurementofover ≥ 94 cm forWhite andBlackmen and≥ 80 cm forWhit
Asianmen and/or
" systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg or tr
" HDL-cholesterol ≤ 0.35 g/l (0.9mM) or triglycerides ≥ 2 g/l (2.2mM) or treated dy
b)Women with a history of gestational diabetes or with a child weighing > 4 kg at bi
c) People with history of temporarily induced diabetes, e.g. steroids,
d) People who have ischaemic heart disease, cerebrovascular disease, peripheral vas
e)Women with polycystic ovary syndrome who have a BMI ≥ 30 kg/m²,
f) People who have severemental health problems and/or receiving long term anti-p
g) People with a history of IGTor IFG.
Paulweber B et al. IMAGE-Gtered questionnaires may also be used to identify people at risk
(e.g. by anyone on the Internet, or in pharmacies, or as part of na-
tional health surveys) and used to prompt further diagnostic test-
ing by a health care provider. If a person is considered to be at in-
creased risk for diabetes, they will proceed to PG measurements
(either fasting or preferably using an OGTT). At the very least,
measurement of random capillary blood glucose can be used
with an improved performance if measurement is done in the
postprandial period [217]. A high HbA1c level may also identify
a subset of asymptomatic people with diabetes. Indeed, the sen-
sitivity of HbA1c measurement for the screening of undiagnosed
diabetes was found to be fairly good as compared to FPG [218].
HbA1c was less sensitive for detecting prediabetes or diabetes
when compared to OGTT results [219]. The available resources
may define the testing regime used in each country/locality.
Clinical practice-based strategies
A diagnostic test may be used in routine clinical practice but as it
is time-consuming, one may propose to select the patients with
at least one obvious risk factor for diabetes, such as age > 40 years,
overweight or obesity, components of the MetSy, family historyTable 5 IMAGE criteria for
screening for diabetes and predia-
betes within target populations
ions
roups agedover 25 yearswith 1 ormore of
e, Black andAsianwomen, and ≥ 90 cm for
eated hypertension and/or
slipidemia
rth,
cular disease,
sychotic drugs,
uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 6 Suggested priorities for diabetes prevention
Highest priority
" persons with IGT (IGT ± IFG) (Evidence A)
High priority
" persons with isolated IFG (Evidence C)
" persons withMetSy (age (45 years) as defined by the ATPIII criteria or other
criteria which are associated with increased T2D risk (e.g. IDF criteria for
MetSy) (Evidence C).
Medium priority
" persons with overweight, obesity, or physical inactivity (Evidence C)
Low priority
" general population (Evidence C)
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factors are identified in the sections above, and have been consid-
ered in other recent guidelines, including IDF [172], Diabetes UK
[220], France [221], American Diabetes Association [222], that all
recommend targeted or opportunistic screening of high risk indi-
viduals. Some of these recommendations have already been vali-
dated [223]. l" Table 5 summarizes the populations we recom-
mend for targeted screening (Evidence I, B). Systematically tar-
geted screening programmes may be possible here. For example,
GPs or health insurance companies with computerised databases
can pro-actively identify all people with various combinations of
risk factors and post the questionnaires to these targeted groups.
A screening strategy may consist of PGmeasurement at fasting or
even better of OGTT due to its higher sensitivity. One alternative
may be a stepped approach including an initial screening ques-
tionnaire in the process (l" Fig. 1). Two risk factors, obesity and
CVD, provide some examples for the operation of a targeted
screening process.
Cosson et al. [224] performed OGTT in 933 overweight or obese
patients with mean age of 39 years and free of known glycemic
abnormalities. Their FINDRISC score was retrospectively calcu-
lated using the clinical files. Prediabetes or diabetes was diag-
nosed in 26% of the subjects of whom 75% would not have been
diagnosedwith FPG alone. Selecting the subjects with a FINDRISC
≥ 11 to be screened directly with an OGTT had a sensitivity of
78%, a specificity of 44% and limited the number of OGTTs to
575 (60% of the study sample) [224] (B).
In patients with established CVD but without known diabetes:
the percentage of those who have IFG or unknown diabetes ac-
cording to FPG is higher than 17%, but the percentage of those
with prediabetes or diabetes according to OGTT is far higher
(> 50%). In other words among patients with CVD and glucose ab-
normalities, in most cases it is the 2-hour PG which is elevated,
whereas FPG is often normal [225]. Therefore, in patients with
CVD a scoring diabetes risk test can be applied but an OGTT
should be carried out in all patients [226] (B).
In practice, the screening strategy depends on local possibilities.
However, due to the very high number of obese subjects, OGTT is
perhaps best reserved for those with higher scores, whereas the
very high prevalence of diabetes or prediabetes in CVD patients
suggests that performing OGTT routinely in these patients is the
best strategy (l" Table 6).
Recommendations
A As OGTT has a higher sensitivity than FPG for detecting diabe-
tes and is the only test to detect IGT, a definite categorization of
glycemic state needs an OGTT.
A Several risk scores are available and valuable for detecting cur-
rent undiagnosed diabetes and/or to rate the risk for developing
T2DM. The FINDRISC meets the requirements of being a simple,
non-invasive and inexpensive tool and has been shown to be a
reliable tool both for detecting undiagnosed diabetes and for pre-
dicting future diabetes risk in several European cohorts.
B Performance of diabetes risk scoresmust be assessed in the tar-
get population where they will be ultimately applied.
A After scoring for diabetes risk, it is mandatory to inform partic-
ipants about their risk and to take time to deliver explanations, in
particular to low educated individuals. This needs to be done ap-
propriately in order to raise the awareness and understanding of
T2DM and its risk factors, while avoiding or minimizing negative
effects, such as emotional distress and denial [216].Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201A A community-based strategy should consist of using a screen-
ing test as a first step in order to estimate the risk for current dia-
betes or prediabetes and the risk for future diabetes. It is recom-
mended the use of opportunistic screening by health-care per-
sonnel including those working in general practice, nurses and
pharmacists. If after this first step a person is considered to be at
increased risk for diabetes, they will proceed to PG measure-
ments (either fasting or preferably using an OGTT) in order to de-
termine more precisely their glycemic status.
B In routine clinical practice, a screening strategy should be tar-
geted to patients with at least one obvious risk factor for diabetes.
It may consist of PG measurement at fasting or even better of
OGTT due to its higher sensitivity. One alternative may be a
stepped approach including an initial screening questionnaire
(score of risk for diabetes) in the process. As examples, due to
the very high number of obese subjects, OGTT is best reserved
for those with higher scores, whereas the very high prevalence
of diabetes or prediabetes in CVD patients suggests that perform-
ing OGTT routinely in these patients is the best strategy.Prevention of T2DM and its Comorbidities
!
Methodology
This section was compiled following a systematic search for pri-
mary studies, systematic reviews and meta-analyses [69,178] of
research on preventing the onset of T2DM. The initial search was
undertaken using MEDLINE with follow-up of cited references.
The final selection was limited to randomized controlled trials
(RCTs) published in English between1979 and 2008, which fea-
tured development of T2DM as a study endpoint and used stan-
dard criteria for the diagnosis of diabetes mellitus. Key data from
the major studies are summarized in (l" Tables 7, 8, 9).
Findings for prevention by lifestyle modification
Major T2DM prevention studies
Da-Qing Study (CDQDPS) [184,227]. Cluster randomisation was
used to allocate 577 people with IGT attending 33 participating
clinics to diet alone, exercise alone, diet-and-exercise combined
or no intervention. The participants in the dietary intervention
were encouraged to reduce weight aiming at < 24 kg/m2, other-
wise high-carbohydrate (55–65 E%) and moderate-fat (25–30 E
%) diet was recommended. Participants were encouraged to con-
sumemore vegetables, reduce simple sugar intake and control al-
cohol intake. The participants in the exercise intervention were
encouraged to increase their level of leisure-time physical activ-
ity by at least 1–2 “units” per day, one unit corresponding for in-0; 42 (Suppl. 1): S3–S36
Table 7 Characteristics of lifestyle intervention studies to prevent type 2 diabetes
Ref. Acronym Design Intervention (int, D = diet, PA = physical activity) Follow-up (years) DROP out
[184,227] CDQDPS Cluster
randomized
D: increase vegetables, decrease alcohol and sugar,
caloric and weight reduction if overweight
6 [104] (int) 44/577 (8%) at 6 years
PA: 1–2 units/day; 1 unit = 30min slow walking/house
cleaning, 20min fast walking/cycling, or 5min jumping
rope/swimming),
D + PA: individual counselling + compliance evaluation
by physician/nurse every 3m + small groups weekly for
1m, monthly for 3m and every 3m thereafter
20 [105]
(int + follow-up)
14/577 (2%) at 20
years
[231,232,
320,321]
DPS RCT D + PA: weight reduction 5% ormore; D: < 30 E% fat,
< 10 E% sat fat, 15 g fibres/1000 kcal; PA: ≥ 30min/day
3.2 [193] (int) 42/522 (8%) at 3.2
years
Individual, personalized dietary counselling; 7 sessions
during the first year and every 3m thereafter voluntary
gym 1–2 sessions/w
7 [195]
(int + follow-up)
47/522 (9%) at 7 years
[234,322] DPP RCT D + PA: weight reduction 7% 2.8 7.5%
D: 25 E% fat
PA (e.g. brisk walking) 150min/week (700 kcal/w)
Goal-based behavioural intervention; case-managers
(1/20–26 participants)
16-session core curriculum in groups during the first
24 w; individual session every 2m thereafter + “toolbox
funds” ($100/participant/year) for expenses (cook-
books, personal trainer, aerobic tapes, reinforcers for
fulfilling behavioural contracts etc.)
[186,235] IDPP RCT D + PA 2.5 1.5% (con)
D: decrease energy, refined carbohydrates and fats,
avoidance of sugar and inclusion of fibre-rich foods
9% (int)
Face-to-face counselling at baseline and every 6m; tele-
phone contacts at two weeks andmonthly thereafter
PA: Brisk walking 30min/day ormore (or comparable
physical labour or other activity)
[187] Japanese trial in
IGTmales
RCT (1 :4) Intensive vs. standard intervention: 4 5.6% (con), 4.7% (int)
at year 1
BMI goal < 22 kg/m2
D: reduce amount by 10% (smaller rice bowl etc.),
increase vegetables; total fat < 50 g/day, alcohol < 50 g/
day; eating out ≤ 1/day
PA: walking 30–40min/day
Face-to-face counselling in hospital every 2–3m
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l.stance for 30 minutes of slow walking, 20 minutes of cycling,
10 minutes of slow running, or 5 minutes of swimming. The cu-
mulative 6-year incidence of T2DM was lower in all intervention
groups (41–46%) compared with the control group (68%). A 20-
year follow-up [184] found that the incidence of T2DM was per-
sistently lower in the combined intervention group compared
with the control group. There were no statistically significant dif-
ferences in CVD events, CVD mortality, or total mortality be-
tween the control group and the combined intervention groups,
on the other hand, the study was under-powered to detect such
effects. Although the non-significant 17% reduction in death
from CVD is suggestive of an effect, lifestyle intervention has not
yet been proven to prevent CVD morbidity and mortality in per-
sons at high risk for T2DM and further, well-powered studies are
needed to confirm this. Nevertheless, there is preliminary evi-
dence from CDQDPS [228] and other studies [229,230].
Finnish Diabetes Prevention Study (DPS) [185,231,232]. A total
of 522 middle-aged, overweight individuals with IGT were allo-
cated either to a the intensive lifestyle intervention or to the con-
trol group. The intervention included individualized advice and
behavioural support to achieve the intervention goals: bodyPaulweber B et al. IMAGE-Gweight reduction of ≥ 5%, total fat intake < 30% of energy, satu-
rated fat intake < 10% of energy, fibre intake of ≥ 15 g/1000 kcal,
and moderate exercise for ≥ 30min/day. Consumption of whole-
meal products, vegetables, berries and fruit, low-fat milk and
meat products, soft margarines, and vegetable oils rich in mono-
unsaturated fatty acids were recommended. The participants
were also individually guided to increase their level of physical ac-
tivity and individually tailored circuit-type resistance training
sessions were also offered to improve the functional capacity and
strength of the large muscle groups. The control group received
only general advice about healthy lifestyle at baseline. Body
weight reductions from baseline to years 1 and 3 were 4.5 kg and
3.5 kg respectively in the intervention group and 1.0 kg and 0.9 kg
in the control group. The cumulative incidence of T2DMwas 11%
[CI 6, 15%] in the intervention group and 23% [95% CI 17, 29%] in
the control group after 4 years, with 58% relative risk reduction.
None of those achieving all five lifestyle goals developed T2DM.
Post hoc analyses showed that adopting a diet with moderate fat
andhigh fibre content [233], aswell as increasing physical activity
[97] were independently associated with a reduced risk of T2DM.
After a median of seven years follow-up, the marked reduction in
the cumulative incidence of T2DMwas sustained.uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 8 Population characteristics (means) of lifestyle intervention studies to prevent type 2 diabetes
Ref. Acronym Age
(years)
BMI
(kg/m2)
Waist (cm)
(male/female)
Blood pressure
(mmHg)
Lipids TC
(mmol/l)
MetSy
(%)
FPG
(mmol/l)
[184,227] CDQDPS 45 26 – 134/89 (con) 5.3 – 5.5
132/87 (int) 5.2 5.6
[231,232,
320,321]
DPS 55 31 101 138/86 5.6 74% 6.1
[234,322] DPP 50 34 105 – – 53% 5.9
[186,235] IDPP 45 (con) 26 91/86 124/76 5.1 46%
46 (int) 26 89/88 122/74 5.2
[187] Japanese trial in
IGTmales
30–60 24 – 124/79 (con) TC – 6.2
123/78 (int) 5.5 6.3
Table 9 Main results and outcome of lifestyle intervention studies to prevent type 2 diabetes
Ref. Intervention Number of T2DM cases
(per 100 person years)
Risk reduction Numbers-
needed-to-treat
[184–227] CDQDPS At 6 years: At 6 years: 4.2 (D)
90/133 (con) = 15.7 DRR (adjusted): 3.8 (PA)
57/130 (D) = 10.0 0.69 (D), p < 0.3 4.6 (D + PA)
58/141 (PA) = 8.3 0.54 (PA), p < 0.0005 for 6 years
58/126 (D + PA) = 9.6 0.58 (diet + PA), p < 0.005; no diff. between ints
At 20 years: At 20 years:
11.3 (con) Adjusted HRR:
6.9 (combined int) 0.57 (combined int)
[231,232,320,321] DPS At 3.2 years: At 3.2 years: 22 for 1 year
59/257 (con) = 7.8 HRR 0.42, p < 0.001
27/265 (int) = 3.2
At 7 years: At 7 years:
110/257 (cont) = 7.4 HRR 0.57, p < 0.001
75/257 (int) = 4.3
[234,322] DPP 11.0 (con) HRR 0.42 6.9 for 3 years
4.8 (int)
[186,235] IDPP 3-years cumulative incidence:
55.0% (con), 39.3% (int)
RRR 28.5%, p = 0.018 6.4 for 3 years
[187] Japanese trial in
IGTmales
4-years cumulative incidence:
9.3% (con), 3.0% (int)
RRR 67.4%, p < 0.001
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The DPP compared the efficacy of intensive lifestyle intervention
and standard lifestyle recommendations; the study also had a
metformin arm. A total of 3234 high-risk individuals with IGT
and slightly elevated FPG were recruited. Lifestyle intervention
in DPP was primarily undertaken by “case managers”. The goals
were to achieve and maintain 7% weight reduction by consuming
healthy, low-calorie, low-fat diet and to engage in physical activ-
ities of moderate intensity (such as brisk walking) 150 minutes
per week or more. Compared with placebo, lifestyle intervention
reduced T2DM risk by 58% at 2.8 years mean follow-up. Among
the lifestyle intervention group, 74% achieved the physical activ-
ity goal of > 150minutes/week at 24weeks. At one-year themean
weight loss was 7 kg (about 7%). Body weight at baseline and
weight reduction during intervention were most important pre-
dictors of T2DM risk [60]. For each kilogram lost, the risk of T2DM
was reduced by 16%.
Indian DPP (IDPP) [186,235]. A total of 531 subjects with IGT
were randomized into four groups (control, lifestyle modifica-
tion, metformin, and combined lifestylemodification andmetfor-
min). Lifestyle modification included advice on physical activityPaulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201(30 minutes of brisk walking per day) and reduction in total calo-
ries, refined carbohydrates and fats, avoidance of sugar, and in-
clusion of fibre-rich foods. After a median follow-up of 30
months, the relative risk reduction was 29% with lifestyle modi-
fication, 26% with metformin and 28%with lifestyle modification
and metformin, as compared with control.
Japanese Prevention Trial [187]. This trial randomized 458 men
with IGT to receive either an intensive lifestyle intervention or
standard management. Participants in the intensive intervention
group visited hospital every 2–3 months to receive detailed ad-
vise to reduce body weight if BMI was ≥ 22 kg/m2 (by consuming
large amount of vegetables and reducing the total amount of oth-
er food by 10%. Intake of fat (< 50 g per day) and alcohol (< 50 g
per day) were limited and physical activity recommended (30–
40min per day of walking). The intervention group achieved a
67.4% reduction in risk compared with controls. Body weight de-
creased by 2.2 kg and by 0.4 kg in the intervention and control
groups during 4 years.
Other studies relevant to prevention of T2DM by lifestyle mod-
ification. The following studies are not includedwith the “major”0; 42 (Suppl. 1): S3–S36
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l.prevention studies because of a variety of limitations including
low power, inadequate randomization or insufficient description
of the methodology or content of the lifestyle intervention. Some
studies, although not primarily focusing on prevention of T2DM,
have also published findings related to T2DM incidence and are
summarised below.
An early randomised intervention study, the Malmöhus study
[236] included 267 men with IGT and found lower rates of devel-
opment of T2D (13% vs. 29%) in those receiving dietary interven-
tion, although the published report neither defined clearly what
type of diet was advocated nor the degree of adherence.
The “Whitehall Borderline Diabetes Study” [237] assessed the ef-
fectiveness of carbohydrate restriction in the prevention of
T2DM. A total of 204 men with IGT were randomized to one of
four treatment groups: (i) carbohydrate 120 g/day + placebo, (ii)
“control diet“ with sucrose limitation + placebo, (iii) 120 g/day
carbohydrate + 50mg phenformin and (iv) sucrose limitation
+ 50mg phenformin. After 5 years, the incidence of T2DM cases
in each group was as follows: 18%, 13%, 18%, and 9%, with none
of the differences significant.
The feasibility of a diet and exercise intervention was assessed in
217 men with IGT in the Malmö feasibility study [238]. Effects of
exercise training (twice weekly 60-min with various dynamic ac-
tivities) and diet (reduction in refined sugar, simple carbohy-
drates, fat, saturated fat, energy, alcohol and increase in complex
carbohydrates and vegetables) were compared with a non-ran-
domized group receiving no intervention. After 5 years, 11% of
the intervention and 29% of the reference groups had developed
T2DM. The 12-year follow-up [154] revealed that mortality in the
former IGT intervention group was lower than in those who re-
ceived “routine care” only (6.5 and 14.0/1000 person years,
p = 0.009).
In 200 womenwith IGT and previous GDM, intensive versus rou-
tine dietary advice and emphasizing the importance of regular
exercise was tested at the University of Melbourne [240]. Advice
was delivered using a diet sheet and reinforced during frequent
telephone contacts. Annual incidence rates for T2DM were 6.1%
in the intervention group versus 7.3% in controls, with no differ-
ence between groups.
In Auckland [241], 176 subjects with IGT or newly diagnosed
T2DM were randomized to dietary intervention designed solely
to reduce total dietary fat and “usual diet“ controls. Despite lower
2-hour glucose, insulin and incidence of T2DM or IGT at one year
in the intervention group, there was no difference after 5 years.
The SLIM Study [177,178] assessed the effect of a diet and exer-
cise intervention based on general public health recommenda-
tions on glucose tolerance, insulin resistance, and CVD risk fac-
tors in individuals with IGT. Altogether 147 participants with
IGT were randomised to receive either intensive lifestyle inter-
vention or standard care. After three years, meanweight changes
were greater in the intervention than in the control group (1.1 kg
and + 0.2 kg; p = 0.011). Desired changes in insulin resistance and
2-h glucose were observed only in the intervention group.
Among the 106 who completed the intervention, the cumulative
incidence of T2DMwas 18% in the intervention group and 38% in
the control group, a relative risk 0.42 (p = 0.025), representing a
58% risk reduction. However an intention-to-treat analysis,
which included 121participants, attenuated the effect with a
non-significant relative risk (RR) of 0.58 (p = 0.07).
The primary aim of The Multiple Risk Factor Intervention Trial
(MRFIT) [242] was prevention of coronary heart disease (CHD)
among 12866 men at high CHD risk, followed up over 6–7 years.Paulweber B et al. IMAGE-GThe intervention included dietary counselling aimed at reducing
saturated fat and cholesterol and increasing polyunsaturated fat,
and body weight reduction if needed. In the intervention group,
11.5% developed T2DM, compared with 10.8% of the control
group with a HR of 1.08 [95% CI: 0.96, 1.20]. However, among
smokers HRwas 1.26 [95% CI 1.10, 1.45] and among non-smokers
0.82 [95% CI 0.68, 0.98] (p = 0.0003). Thus, the intervention re-
duced the risk of T2DM only among non-smokers.
A one-year trial in Italy [243] compared the effectiveness of a
structured lifestyle intervention program in reducing the onset
of the MetSy or T2DM in 375 persons with metabolic disorders
recruited from a population-based cohort. Intervention consisted
of general information from family physician (control group), fol-
lowed by 5 training sessions with structured core but flexible
contents (intervention group only) in line with general dietary
recommendations (50–60% of energy as carbohydrates, < 30%
energy as fat, < 10% energy as saturated fat, 15–20% energy as
protein, and 20 to 30 g fibre/day) and with individualized exer-
cise andweight loss goals. After one year, 1.8% of the intervention
group and 7.2 of the control group had developed T2DM, with an
odds ratio (OR) of 0.23 [95% CI 0.06, 0.85] (p = 0.03).
Prevention of T2DM in children and adolescents
Applying the predefined search criteria failed to identify any
RCTs designed to prevent the onset of T2DM in children or ado-
lescents and there is a need for “long-term studies of multi-eth-
nic cohorts followed into adulthood to determine the natural his-
tory and effectiveness of intervention strategies, particularly life-
style“ [10]. Expert opinion, drawingmainly on evidence in adults,
identifies weight loss and/or prevention of weight gain as the
best way to prevent T2DM. The American Academy of Pediatrics
has made the following recommendations: supporting breast
feeding, promoting healthy eating habits and physical activity, i.
e. discouraging sedentary activities such as watching TV or play-
ing video games, screening for family readiness for change, edu-
cation about complications of obesity, maintaining normal,
healthy body weight, and avoidance of smoking [244,245]. At
present, the evidence for the long-term effectiveness of obesity
prevention programs in children and adolescents is insufficient.
The best results have been obtained when schools and family
are involved [246]. Nevertheless, on the basis of evidence on the
determinants of obesity, lifestyle changes are strongly recom-
mended for all children and adolescents at risk for overweight,
IGT and T2DM.
Recommendations
A Intensive lifestyle interventions that encourage people to
change their diet and to increase their level of physical activity
should be used to prevent or delay the onset of T2DM in adults
with IGT. The NNT for prevention of one case of T2DM of 6.4
[95% CI 5.0, 8.4] at mean follow up ranging from 1.83 to 4.62
years [247].
A Weight reduction is an essential element of prevention of
T2DM prevention. Sustained weight reduction by 5–7% is suffi-
cient to substantially lower the risk of T2DM.
B An increase in physical activity even at a level of 30 minutes
per day of moderate exercise reduces the risk of T2DM and is
therefore recommended.
B A diet with high fibre (≥ 15 g per 1000 kcal), moderate fat
(≤ 35% of total energy) reduced saturated and trans fat (< 10% of
total energy) can lower body weight and reduce the risk of T2DM
and is therefore recommended.uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 10 Characteristics of pharmacological intervention studies to prevent type 2 diabetes
Ref. Acronym Design Intervention (D = diet, PA = physical
activity, P = placebo)
Follow up
(years)
Drop
out
Adverse effects
[249] SMOMS RCT, DB, PC 8-w very-low-calorie D, then D + PA 3 gastrointestinal
+ Orlistat, O, 3 × 120mg/d, (n = 153) 33% 88%
+ P (n = 156) 37% 63%
[250] XENDOS RCT, DB, PC Low caloric D + PA 4 gastrointestinal
+ Orlistat, O, 3 × 120mg/d, (n = 1640) 48% 36%
+ P (n = 1637) 66% 23%
[258] BOTNIA RCT, DB, PC, + 12m
wash out
1.5 hypoglycemia
Glipizide, G, 2.5 mg7d, (n = 17) 1 41%
P (n = 17) 32%
[255] STOP-
NIDDM
RCT, DB, 3-m wash-
out: data not avail-
able
D + PA prescription gastrointestinal
+ Acarbose, A, 3 × 100mg/d, (n = 682) 3.3 30% 13%
+P (n = 686) 3.5 18% 3%
[65,260] DPP RCT, DB, intention-
to-treat
Standard lifestyle recommendation 2.8 7.5% gastrointestinal
(events/100 person-yr)
+ Metformin, M, 2 × 850mg/d, (n = 1037) M: 78, D + PA: 24, p: 31
+ Intensified D + PA (n = 1079)
+ P (n = 1082)
+ Troglitazone, T, discontinued due to safety 31
[186] IDPP RT Individual Dmodification 2.5 26 gastrointestinal
+ Standard lifestyle advice (con, n = 136) M, D + PA +M: 5
+ D + PA (n = 133) hypoglycemic
symptoms:
+ Metformin, M, 2 × 500/250mg/d, (n = 133) M, D + PA +M: 22
+ Combined D + PA +M (n = 129)
[262] TRIPOD RCT, DB,PC, open-
label follow-up
Lifestyle (standard D + PA) –
+ Troglitazone, T, 400mg/d, (n = 133) 2.6 19
+ D + PA (n = 133) 2.3 11
[188] DREAM RCT, DB, PC, 2 × 2
factorial design
+ 2–3mwash out
17-d SB P run-in, compliant patients enrolled,
D + PA
3 CVevents/HF
RO + Rosiglitazone, RO, 8mg/d, (n = 2635) 75/14
+ P + lifestyle (n = 2634) 772 55/2
658 ns/p = 0.01
[264] DREAM RCT, DB, PC, 2 × 2
factorial design
+2–3mwash out
+ Ramipril, RA, ‑15mg/d, (n = 2623) 3 27% cough/angioedema:
9.7%/0.1%
RA + P + lifestyle (n = 2646) 22% 1.8%/0.2%
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l.C Comorbidities, particularly MetSy, should be monitored and
taken into account while planning the diet [119,248].
C Currently there is no evidence from long-term prevention
studies that reducing total dietary carbohydrate prevents T2DM.
Carbohydrate sources should mainly be whole-grain cereal, fruit,
vegetables, and legumes.
D There is no evidence from clinical trials of the effectiveness of
interventions to prevent the onset of T2DM among children and
adolescents. However, on the basis of physiological evidence and
research in adults it can reasonably be assumed that maintaining
a healthy weight through physical activity and balanced/healthy
nutrition is the key factor will be important to prevent or post-
pone the onset of T2DM among youth.
Findings for prevention by pharmaceutical treatment
Studies of the effectiveness of drug treatment in preventing or
delaying the onset of T2DM have been performed mostly in per-
sons at high-risk of T2DM, such as those who are obese and/orPaulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201exhibit IGT, or women with a history of GDM. Key data of these
studies are summarized in l" Tables 10, 11, 12.
Antiobesity treatment
Orlistat. The Scandinavian Multicenter Orlistat in Metabolic Syn-
drome (SMOMS) study was performed in obese subjects with the
MetSy (n = 309). After 8-weeks on a very-low caloric diet, partic-
ipants were given the intestinal lipase inhibitor, orlistat or place-
bo in addition to lifestyle modification. Over 36 months the inci-
dence of diabetes was 58% lower in the orlistat group compared
with placebo, with no differences in insulin secretion and activity
[249].
The XEnical in the prevention of Diabetes in Obese Subjects
(XENDOS) study was conducted in 3277 obese subjects, of whom
694 had IGT. They received orlistat or placebo in addition to life-
stylemodification. After amedian follow up of 48months, the HR
for all patients was 0.59 (p = 0.028), for those with IGT it was 0.550; 42 (Suppl. 1): S3–S36
Table 11 Population characteristics (means) of pharmacological intervention studies to prevent type 2 diabetes
Ref. Acronym Age
(years)
BMI
(kg/m²)
Waist (cm)
(male/
female)
Blood
pressure
(mmHg)
Lipids
HDL‑C
(mmol/l)
Lipids TG
(mmol/l)
MetSy or
diabetes risk
FPG
(mmol/l)
[249] SMOMS 47 (O) 37 119 144/91 1.1 2.4 309 Obese + MetSy 6.4
47 (P) 38 119 144/91 1.2 2.5 6.3
[250] XENDOS 43 (O) 37 115 131/82 1.2 1.9 3277 Obese, 694 IGT 4.6
44 (P) 37 115 130/82 1.2 1.9 4.6
[258] BOTNIA 58 (G) 28 88 143/88 1.0 1.8 First-degree relatives +
IGT
5.3
53 (P) 29 90 134/83 1.1 1.6 5.3
[255] STOP-
NIDDM
54 (A) 31 102 131 1.2 2.1 1429 IGT + IFGa 6·2
55 (P) 31 102 131 1.2 2.1 6.2
[65] DPP 51 34 105 125/79 1.0 – 3234 IGT + IFG 6.0
[186] IDPP 35–55 26 124 (con) 1, 1.9 531 IGT
122 (D + PA) 2, 2.0
121 (M) 3, 1.7
123
(D + PA +M)
4, 1.8
[262] TRIPOD 35 (T) 31 – – – – 266 pGDM, 63% IGT 5.3
34 (P) 30 5.2
[188] DREAM-
Rosi
55 (Ro) 31 101/96 136/83 – – 739 IFG, 4530 IGT 5.8
55 (P) 31 102/96 136/84 5.8
[264] DREAM-
Rami
55 (Ra) 31 136/83 IGT: 1513 (Ra), 1515
(P)
5.9
55 (P) 31 – 136/83 – – IFG: 366 (Ra), 373 (P) 5.9
a 90% family history of diabetes, 78% BMI > 27 kg/m2, 53% > 1 risk factor for T2DM, 51% high blood pressure, 48% dyslipidemia, 23% women with a history of gestational diabetes
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l.(p = 0.0024), but there was no difference in the rate of progres-
sion from NGT to IGT [250].
Rimonabant. One sub-group analysis of the Rimonabant-In-Obe-
sity (RIO)-Europe study compared effects of the endocannabi-
noid receptor antagonist rimonabant (n = 399) with placebo
(n = 123) as part of a lifestyle intervention in healthy obese sub-
jects with a mean BMI of 36 kg/m2 [251]. Within 24 months, ri-
monabant treatment achieved weight reduction and improve-
ment of HDL‑C and triglycerides. Although only 0.5% of the rimo-
nabant group, compared with 4.1% of the control group, devel-
oped diabetes, the high drop-out rates (58% and 55%) and low in-
cidence of T2DM limit the relevance of the study. In October
2008, rimonabant was withdrawn from the market because of
concerns about risk-benefit ratios so that it cannot be used for
diabetes prevention [251].
Bariatric surgery. The Swedish Obesity Surgery (SOS) trial
studied 2010 severely obese subjects (BMI > 35 kg/m2) who
underwent surgery for obesity (gastric banding, gastroplasty,
gastric bypass) and 2037 patients who chose conventional treat-
ment in a matched pairs-design non-randomized study. Subjects
undergoing surgery achieved a reduction in body weight of 20–
30 kg, accompanied by a reduction in cardiovascular risk factors.
After 8 years, the surgical group had a greatly reduced risk of de-
veloping diabetes (OR: 0.16) [252]. Two recent reviews analyzed
the available evidence for the use of bariatric surgery in overt di-
abetic and in obese patients. While surgery improved T2DM in
87% and resolved it in 79% of cases [253] and was more efficient
than conventional treatment to induce weight loss in obese pa-
tients [254], the evidence on safety is less clear due to limited
number and quality of studies [254].Paulweber B et al. IMAGE-GOral glucose lowering drugs
Alpha glucosidase inhibitors. In the Study-To-Prevent-NIDDM
(STOP-NIDDM), persons with IGT (n = 1.429) were randomized
in a double-blind trial to either the alpha glucosidase inhibitor,
Acarbose, or placebo. After a mean follow-up of 3.3 years, the
acarbose-treated group achieved 25% and 36% RR reduction
based on one or two OGTTs in progression to diabetes compared
with placebo. The effect of acarbose was observed across all ages,
at all BMIs, and in both sexes, while there was some evidence of
an accompanying improvement in CVD risks [255–257].
Sulfonylurea.Within the BOTNIA study, 34 first-degree relatives
of patients with T2DM and IGTwere assigned randomly to either
glipizide or placebo. At 6 months of treatment, measures of insu-
lin secretion/action such as fasting plasma insulin and measures
of insulin resistance and HDL‑C had improved in the glipizide
group. Thereafter, the treatment was withdrawn and the partici-
pants observed for another 12 months of washout. At 18 months,
both FPG and 2-h PG were lower in the glipizide than in the pla-
cebo group. The prevalence of T2DM was 29.4% in the placebo
group and 5.9% in the glipizide group, corresponding to an 80%
relative risk reduction at 18 months. However, although not
reaching statistical significance in this study, there was some evi-
dence suggesting a need for caution in the use of glipizide be-
cause of an increased frequency of symptoms suggesting hypo-
glycemia [258].
Biguanides. As described above, the Whitehall Borderline Diabe-
tes Study examined the ability of carbohydrate restriction to pre-
vent the onset of diabetes inmenwith IGT (n = 204) with or with-
out treatment with phenformin, but detected no difference in theuideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 12 Main results and outcome of pharmacological intervention studies to prevent type 2 diabetes
Ref. Acronym Number of T2DM cases per group Risk reduction Number needed to treat
[249] SMOMS O: 8 (5.2%) HR: 0.63 –
P: 17 (10.9%)
[250] XENDOS O: 102 (6.2%) HR for all: 0.59, p = 0.028) 10 IGTs/4years
P: 147 (9.0%) HR for IGT: 0.55, p = 0.0024c
[258] BOTNIA V: 5.9% ARR: 23.5% –
P: 29.4% HR = 0.30
[255] STOP-NIDDM V: 105 (15%) ARR: 8.7% –
P: 165 (24%) HR: 0.64, p = 0·0003
[65] DPP Incidence/100 person-years: RRR:
D + PA: 4.8 D + PA vs. P: 58% 6.9/3 years (D + PA)
M: 7.8 M vs. P: 31% 13.9/3 years (M)
P: 11.0 D + PA vs. M: 39%
[186] IDPP D + PA: 0.623, p = 0.018 HR: D + PA: 0.62, p = 0.018 6.4/3 years
M: 0.651, p = 0.029 M: 0.65, p = 0.029 6.9/3 years
D + PA +M: 0.629, p = 0.022 D + PA +M: 0.63, p = 0.022 6.5/3 years
[262] TRIPOD T: 30% (12.1%/y) HR: 0.45 (non-adjusted), 0.44 (adjusted) –
P: 14% (5.4%/y)
[188] DREAM-RO RO: 280 (10.6%) HR: 0.38, p < 0.0001b 6.9/3 years
P: 658 (25.0%) a
[264] DREAM-RA RA: 17.1% (449) HR: 0.91 –
P: 18.5% (489)
a CV events: RO: 306 (11.6%), P: 686 (26.0%); b Composite primary endpoint: HR: 0·40, p < 0·0001; c Progression NGT to IGT: no difference
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l.incidence of diabetes between the different groups after 45 years
[259].
As decribed above, the US DPP, a multicenter RCT, tests an inten-
sive lifestyle intervention with metformin (850mg twice daily),
or troglitazone (400mg daily) or placebo [260] in high-risk per-
sons with IGT (n = 3.234) and slightly elevated fasting plasma glu-
cose (> 5.5mmol/l), with about 45% of the study population from
Non-Caucasian groups such as African-American and Hispanic.
After a mean follow-up of 2.8 years, the relative reductions in
the progression to diabetes were 58% in the lifestyle group and
31% in the metformin vs. placebo-treatment. As these data were
based on an OGGT performed during ongoing treatment, another
OGTT was performed after a 1–2-weeks washout period. After
the washout, diabetes was slightly but not significantly more
common in the metformin group with a OR of 1.49 ([0.93, 2.38]
p = 0.098). Comparison of the probabilities of developing diabetes
during the DPP and during thewash out period revealed that 26%
of the metformin effect did not persist upon drug withdrawal.
Nevertheless, metformin still reduced the incidence of diabetes
by 25% [65].
The IDPP studied persons with IGT (n = 531) who were slightly
younger and less overweight than in DPP and DPS. They received
the following interventions: control, lifestyle modification, met-
formin or combined lifestyle modification + metformin. After
median follow-up of 30 months, the relative risk reductions ver-
sus control were between 26–29% for all study arms. The lifestyle
intervention was less intensive and the diabetes incidence was
higher (55.0% in 3 years) than in the DPP and DPS. Of note, as in
the Indian Diabetes Prevention Study, metformin, when added to
lifestyle intervention exerted no benefit beyond that of the life-
style intervention [186].
Thiazolidendiones. “Insulin sensitizer” such as thiazolidine-
diones which are agonists at the peroxisome proliferator activa-
tor receptor-gamma have been also tested in prevention. The tro-
glitazone arm of the DPP was discontinued because of concerns
about liver toxicity. Before discontinuation (at a mean of 0.9Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201years), the incidence of diabetes was 3.0/100 person-years was
not different versus intensive lifestyle intervention, but lower
than in the placebo and metformin arms. During the 3 years after
troglitazone withdrawal, the incidence of diabetes was compara-
ble to that in the placebo group indicating that its effect did not
persist upon withdrawal [261].
In the Troglitazone In Prevention of Diabetes (TRIPOD) study, His-
panic women with previous gestational diabetes (n = 235) were
randomized to receive the troglitazone, since withdrawn from
sale, or placebo. After a median follow-up of 30 months, the inci-
dence of T2DM was 5.4% and 12.1% with troglitazone and place-
bo. Thus, troglitazone treatment was associated with a 56% rela-
tive reduction in progression to diabetes which remained even
after an 8-mwashout period [262].
The Pioglitazone In Prevention of Diabetes (PIPOD) study was
performed as an open-label observational trial using pioglita-
zone (45mg daily) in 89 women participating in TRIPOD, of
whom 30 had received verum during the previous study. After a
median follow-up of 36 months, 65 women had completed all
study visits: The rates of annual and cumulative incidence of dia-
betes were 5.2% and 17%. It is noteworthy that parameters of in-
sulin resistance were not affected, whereas body weight in-
creased [263].
In the Diabetes REduction Assessment with ramipril and rosigli-
tazone Medication (DREAM) Study, 5.269 adults with IFG or IGT,
or both, and no previous cardiovascular disease were randomly
assigned to receive rosiglitazone (8mg daily) vs. placebo or rami-
pril (up to 15mg) vs. placebo. After a median follow up of 3 years,
rosiglitazone treatment reduced the incidence of T2DM as as-
sessed from a HR of 0.38 [95% CI 0.33, 0.44] (p < 0.0001) and of
the composite primary end point (death or onset of diabetes:
hazard ratio (HR: 0.40 [0.35; 0.46]) (p < 0.0001). In addition, rosi-
glitazone for 3 years increased the likelihood of regression to nor-
moglycemia in adults with IFG or IGT, or both [188,264].
Antihypertensive and lipid-lowering drugs. Several meta-analy-
ses and reviews of studies on angiotensin receptor (AT1) blockers0; 42 (Suppl. 1): S3–S36
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l.or angiotensin converting enzyme inhibitors (ACEI) report an as-
sociation with reduced risk of T2DM [265,266]. However, occur-
rence of diabeteswas not a primary endpoint in these studies and
the methods used to diagnose and detect diabetes were hetero-
geneous. No prospective RCT had examined the ability of antihy-
pertensive drugs to prevent diabetes prior to the DREAM study.
After a median follow up of 3 years, ramipril treatment was not
associated with lower incidence of diabetes at a HR of 0.91 [0.80,
1.03] or death, but with increased probability (“HR” 1.16, p =
0.001) of regression to normoglycemia compared with placebo.
At the end of the study, the median 2-h PG but not FPG was
slightly lower in the ramipril than in the placebo group (p =
0.01) [264].
Post hoc analyses of placebo-controlled statin trials show con-
flicting results on associations between statin therapy and diabe-
tes incidence [267–270]. However, currently, there is no prospec-
tive RCT investigating the effect of lipid lowering drugs on diabe-
tes onset.
Recommendations
A In persons with IGT, metformin and acarbose can be used as
second line strategies for prevention of T2DM, provided that the
drugs are tolerated (gastrointestinal side-effects), and contrain-
dications to metformin therapy (kidney, liver diseases, hypoxic
conditions) are considered [65,179,186,255].
A In obese people with or without IGT, carefully monitored anti-
obesity treatment with orlistat, in addition to intensive lifestyle
modification, can be used as a second line strategy for obese pa-
tients to prevent T2DM.
C In severely obese patients at high risk of T2DM and CVD, bar-
iatric surgery in addition to careful monitoring and lifestyle
change can induce sustained weight loss for [252,271], but long-
term safety is less clear so that it cannot be recommended for dia-
betes prevention at present.
C Glucose lowering drugs such as glipizide or thiazolidendiones
may reduce the risk of T2DM in certain high risk groups, but ei-
ther long-term efficacy or safety are unclear so that these drugs
cannot be recommended for diabetes prevention at present
[179].
C Antihypertensive and lipid-lowering drugs cannot be recom-
mended for the prevention of T2DM at present.
Considerations of societal and public health aspects
International organizations (IDF, EASD, WHO) have issued con-
sensus statements on prevention programs [172,272] and a
number of national or regional programs are already imple-
mented at the societal level [273,274]. The pan-European DE-
plan project further described public health approaches for im-
plementing prevention of T2DM at the primary care level [239].
The majority of the prevention programs designed at community
and national levels are based on implementation of lifestyle in-
terventions in public health and primary healthcare settings
[185]. Data on the efficiency of the population approach are
scarce, but public health surveys demonstrate its utility if based
on the promotion of healthier lifestyle [185,275]. This suggests
that the combination and coordination of individualized and
population approaches at the societal level would be useful
[172]. The health sector cannot implement the population ap-
proach on its own, so other stakeholders (e.g. schools, commun-
ities, politicians, industry/employers) need to be involved [172],
particularly for coordinated prevention in adolescents [276]. Pre-
vention programs also need to address cultural differences in di-Paulweber B et al. IMAGE-Getary habits and physical activity patterns, particularly in minor-
ities [277,278]. Governments should develop and implement na-
tional diabetes prevention plans including a wide range of initia-
tives in different segments of societies such as advocacy (provid-
ing support for relevant associations and organizations and a fa-
vorable economic environment), community support (to produce
a favorable environment for adequate nutrition by education and
for physical activity by sport facilities and urban design), fiscal
and legislative changes (food pricing labeling and advertising as
well as environmental and infrastructure regulation), engaging
of the private sector (promotion of health at workplace and en-
suring healthy policies in food industry) and media support
[172].
Recommendations
A Interventions to prevent T2DM should be implemented at the
societal level though a structured public health plan which
should take into account both high-risk/targeted approach and
population approaches.
C The structured plan should also include specific approaches to
meet the needs of subpopulations, e.g. adolescents, minorities
and disadvantaged groups.
B The establishment and implementation of an effective plan for
the prevention of T2DM at national levels requires government
initiatives comprising advocacy, community support, fiscal and
legislative changes involving infrastructure, engagement of pri-
vate sector and continuous media communication.
A This plan should be part of a network with other relevant pre-
vention programs and public educational activities.Supporting Change in Lifestyle Behaviour for Adults
at Risk of T2DM
!
Changing an existing habit requires people to establish a motiva-
tion or intention to change, make decisions and action plans, rec-
ognise and overcome barriers (both practical and psychological),
initiate the new routine, and then to maintain the new routine,
resisting temptations to relapse back to former habits. Ap-
proaches for supporting changes in diet and physical activity vary
from simple information-giving to more intensive programmes,
which may or may not be based on theoretical models of behav-
iour change [279–283].
Methodology
The recommendations on this topic are based on a systematic re-
view, which summarised the available scientific evidence on the
relationship between increased intervention effectiveness and:
(i) theoretical basis, (ii) behaviour change techniques used, (iii)
mode of delivery, (iv) intervention provider, (v) intervention in-
tensity, (vi) characteristics of the target population (e.g. gender,
ethnicity), (vii) setting. Our systematic “review of reviews” of
the scientific evidence base on dietary and/or physical activity in-
terventions is published separately andwill be available to down-
load from the IMAGE website (http://www.image-project.eu).
Only the key recommendations and a summary of the evidence
are presented here. The review examined systematic reviews,
published between 1998 and 2008, which focused primarily on
populations of adults at risk of developing T2DM and/or CVD. Ar-
ticles were identified by searching multiple electronic databases
of published evidence and other sources. The methodological
quality of studies was systematically assessed using an estab-uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 13 Evidence underlying the recommendations on supporting behaviour change
Evidence Evidence gradea
Overall intervention effectiveness
Dietary or diet plus physical activity interventions can have effects onweight loss.Meannet weight loss in successful interventions varies from
3–5 kg at 12months and from 2–3 kg at 36months
1++
Weight loss from dietary or diet plus physical activity interventions can be sustained for 48months and 7 years (2–3 kg). 1+
Physical activity interventions can have effects at up to 18months of follow up. The increase for successful interventions is 30–60minutes of
moderate activity per week.
1+
Physical activity interventions can also have small effects on weight at up to 12months of follow up (decrease 1–2 kg). 1+
Dietary and/or physical activity interventions can strongly reduceprogression toT2DM(49% relative reduction in risk) at 3.4 years of followup. 1++
Interventions need to paymore attention to behaviour maintenance, once the active phase of intervention is completed. During the active
phase of interventions the net weight loss at 3–12months was on 0.08 bodymass index units per months. During themaintenance phase
(from 6–60months), patients regained weight at a rate of 0.03 bodymass index units per month.
1++
Theoretical basis
Interventions for weight loss (diet or physical activity) which stated a theoretical model as their foundation delivered no greater weight loss
than interventions that did not state their theoretical underpinnings.
2+
Behaviour change techniques
The planned use of established behaviour change techniques in dietary and/or physical activity interventions increases the amount of weight
loss and physical activity produced at 6months of follow up.
1+
Interventionswith diet plus physical activity produce greater weight loss than thosewith dietary change only at up to 24months of follow up. 1+
Interventions based onmotivational interviewing aremore effective than traditional advice at least in the short-term (3 to 6months of follow
up).
1++
Using social support (usually from a family member) increases effectiveness of weight loss interventions at 12months of follow up. 1+
Interventions which include the use of pedometers to self-monitor walking activity producemoderate weight loss andmoderate increases in
moderate levels of physical activity at up to 4months of follow up.
1+
Dietary and/or physical activity interventions which include prompting of self-monitoring alongside other “self-regulatory techniques”
(Specific goal setting; Providing feedback on performance; Review of behavioural goals) produce an average weighted effect sizemore than
twice that of other interventions.
2+
Prompting self-monitoring of behaviour and/or outcomes and prompting self-talk, alongside other intervention techniques (i.e. not in isola-
tion), are associated with increased intervention effectiveness for both dietary and physical activity interventions.
2+
Providing instruction and the use of relapse prevention techniques (for dietary change), prompting practice, individual tailoring, setting goals
and timemanagement (for physical activity) may also enhance intervention effectiveness.
2+
Mode of delivery
Successful physical activity and/or dietary interventions have been delivered using group, individual or combined (individual and group)
modes of delivery.
1++
There is no strong evidence of any difference in the effectiveness of physical activity and/or dietary interventions between individual, group
andmixedmodes of delivery at up to 12months of follow up.
2+
Intervention provider
Successful physical activity and/or dietary interventions have been delivered by doctors, nurses, dieticians/nutritionists, exercise specialists
and lay people. It should be noted however that these providers were often working within a multi-disciplinary team.
1++
There is no strong evidence of any difference in the effectiveness of physical activity and/or dietary interventions delivered bymedically
trained health professionals (doctors, nurses), other professionals (psychologists, counsellors, dieticians, health educators), public health
students, or lay people at up to 12months of follow up.
2+
Intensity
When intensity is considered in terms of intervention duration or total contact time, there is insufficient evidence to draw any clear conclu-
sions about its impact on the effectiveness of dietary and/or physical activity interventions.
–
A greater frequency of meetings, particularly in the active phase of the intervention is associated with greater effectiveness in dietary and/or
physical activity interventions at up to 15months of follow up.
2++
A greater total number of personal contacts/intervention sessions is associated with greater intervention effectiveness at up to 36months of
follow up.
2+
Different populations
Gender: 2+
There seems to be no substantial difference betweenmen and women in responsiveness to dietary and/or physical activity interventions
(once recruited) at up to 16months of follow up. [However, strong gender imbalances in recruiting are reported, so theremay be some types
of intervention which suit womenmore thanmen.]
Older people: 1+
Dietary and/or physical activity interventions can produce weight loss in older populations at up to 34months of follow up.
There is evidence suggesting that older people (over age 45) are more responsive to dietary and/or physical activity interventions at up to
34months of follow up.
2+
Black and minority ethnic groups: 1+
Combined dietary and physical activity intervention can be effective for a wide range of ethnicities, including Caucasian, Afro-Caribbean,
Hispanic, American Indian and Asian (mainly East Asian) populations at up to 34months of follow up.
Disability groups: –
The basic effectiveness of interventions is not yet established in adults with physical limitations. High quality evidence focusing on the effec-
tiveness or relative effectiveness of dietary and/or physical activity interventions in adults with physical limitations or other disabilities is
urgently needed.
(continued)
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Table 14 Definitions of established behaviour change techniques
Source Basis for categorisation of whether studies used established behaviour change techniques or not
Avenell et al. [323] Definitions of behaviour therapy varied by study but include self-monitoring, stimulus control, problem solving, relapse
preventionmanagement, cognitive restructuring, self-assertion, social support, goal setting, self-reinforcement.
McTigue et al. [324] Behavioural interventions are strategies to help patients acquire the skills, motivations, and support to change diet and exer-
cise patterns. These include barrier identification, problem solving, self-monitoring, social support, goal-setting, developing
action plans, relapse prevention, stimulus control, cognitive restructuring.
Shaw et al. [325] Behavioural therapy aims to provide the individual with coping skills to handle various cues to overeat and tomanage lapses in
diet and physical activity when they occur and to providemotivation essential tomaintain adherence to a healthier lifestyle
once the initial enthusiasm for the program has waned. Therapeutic techniques in studies relating to the benefit of using
“established behaviour change techniques” include stimulus control, self-control and therapist-controlled contingencies, self-
monitoring, problem solving, goal setting, behaviour modification, reinforcement.
NICE Obesity Guidance [308] This guidance document comprises a summary of/expansion of reviews by Shawet al. [325], McTigue et al. [324], andAvenell
et al. [323]. Definitions vary by analysis but typically include cue avoidance, self-monitoring, stimulus control, social support,
planning problem solving, cognitive restructuring,modifying thoughts, relapse prevention, reinforcement of change, coping
strategies, coping imagery, goal setting, social assertion, reinforcement techniques for enhancingmotivation.
Table 13 Continued
Evidence Evidence gradea
Settings
Successful interventions have been delivered in a wide range of settings, including health care settings, the workplace, the home, and in the
community. However, evidence on the differential impact of different settings on effectiveness is lacking.
1++
There is tentative evidence that remotely deliveredwalking support interventions (using internet or phone-baseddelivery) can produce short-
term effects on physical activity (at 3 months of follow up).
2+
a Based on SIGN evidence grading system; * Evidence grading is explained in the methods section and in Appendix 2
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l.lished rating system [284] and data were only extracted from re-
views meeting a pre-set quality standard. Selection and data ex-
traction were undertaken independently by two reviewers and
any disagreements resolved by discussion. We identified 3856
potentially relevant articles, of which 30 met the quality and se-
lection criteria. We systematically extracted data relevant to the
specific aims above, rated each piece of evidence, using the SIGN
evidence rating system and produced detailed evidence tables.
Further discussion of the evidence inworkshops of experts in pri-
mary care, behavioural science and diabetes prevention (the IM-
AGE study group) helped to derive the recommendations below.
Findings
The evidence showed that interventions to promote lifestyle
changes are more likely to be effective if they target both diet
and physical activity, mobilise social support, involve the
planned use of established behaviour change techniques (as de-
fined in l" Table 14) and provide a higher frequency of contacts.
Specific techniques to support behaviour change and mainte-
nance were also associated with increased effectiveness. l" Table
13 provides a concise summary of the evidence we examined.
Recommendations
Individual level interventions for people at risk of T2DM should:
A Aim to promote changes in both diet and physical activity
A Use established, well defined behaviour change techniques
(e.g., specific goal-setting, relapse prevention, self-monitoring,
motivational interviewing, prompting self-talk, prompting prac-
tice, individual tailoring, time management), as defined in l" Ta-
ble 14.Paulweber B et al. IMAGE-GD A clear plan of intervention should be developed based on a
systematic analysis of factors preceding, enabling and supporting
behaviour change in the social/organisational context in which
the intervention is to be delivered. The plan should also identify
the processes of change and the specific techniques and method
of delivery designed to achieve these processes. Such planning
should ensure that the behaviour change techniques and strat-
egies used are mutually compatible and well-adapted to the local
delivery context. Following the procedures of the PRECEDE-PRO-
CEED model [285], Intervention Mapping [286], or a similar in-
tervention-design procedure is recommended.
A Work with participants to engage social support for the
planned behaviour change (i.e. engage important others such as
family, friends, and colleagues).
B Maximize the frequency or number of contacts with partici-
pants (within the resources available).
A Include a strong focus on maintenance. It is not clear how best
to achieve this, but behaviour change techniques designed to ad-
dress maintenance include establishing self-monitoring of prog-
ress, providing feedback (e.g. on changes achieved in blood glu-
cose and other risk factors), reviewing of goals, engaging social
support, use of relapse prevention/relapse management tech-
niques and providing follow-up prompts.
C Building on a coherent set of ʼself-regulatoryʼ intervention
techniques (Specific goal setting; Prompting self-monitoring;
Providing feedback on performance; Reviewof behavioural goals)
may provide a good starting point for intervention design. How-
ever, this is by no means the only approach available and It is
worth noting that self-regulation techniques are not normally
used in isolation (e.g. techniques designed to explore and en-uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
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setting).
A Interventions to prevent T2DM may be delivered by a wide
range of people/professions, subject to appropriate training (in-
cluding the use of established behaviour change techniques).
There are examples of successful physical activity and/or dietary
interventions delivered by doctors, nurses, dieticians/nutrition-
ists, exercise specialists and lay people, often working within a
multi-disciplinary team.
A Interventions to prevent T2DM may be delivered in a wide
range of settings. There are examples of successful physical activ-
ity and/or dietary interventions delivered, in health care settings,
the workplace, the home, and in the community.
A Interventions to prevent T2DM may be delivered using group,
individual or mixed modes (individual and group). There are nu-
merous examples of successful physical activity and/or dietary
interventions using each of these delivery modes.
C No specific intervention adaptations are recommended for
men or women, although steps may be needed to increase en-
gagement/recruitment of men.
D People planning interventions should consider what adapta-
tions may be needed for different ethnic groups (particularly
with regard to culturally-specific dietary advice), people with
physical limitations and people with mental health problems.D
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!
Methodology
This section updates and extends a recent systematic review that
focused on environmental determinants of cardiovascular dis-
ease, which shares many risk factors with diabetes [287]. The ini-
tial review employed an iterative process, in which PubMed and
Google were searched, initially using the following search terms:
(environment or community) and (measures or index or risk fac-
tors or determinants), (built environment or nutrition environ-
ment or obesogenic environment or social environment) and car-
diovascular (risk factors or disease), subsequently complemented
by diabetes.
For the review of the economic aspects of diabetes prevention
strategies, PubMed was searched using the terms: (economics of
preventing diabetes), (economics diabetes prevention) and (eco-
nomic evaluation diabetes prevention), with follow up of refer-
ences cited.
To guide the review of health systems issues, a questionnaire was
sent to all IMAGE partners seeking their input as to how they
might implement a model of diabetes prevention in their own
country. It was supplemented by a review of tabled results from
the IMAGE questionnaire “Analyses of Type 2 Diabetes Prevention
Programmes at national level” sent to all IMAGE partners. The re-
sults were then interpreted in the light of a series of studies
undertaken by the European Observatory on Health Systems
and Policies on the health system response to chronic diseases
[288,289], human resources in the health sector [290,291], social
insurance systems [292], and primary care in Europe [293]. This
used, as a conceptual framework, the Chronic Care Model [294],
which was developed in the USA but is now forming the basis of
innovative models of care in several other countries. The compo-
nents of the Chronic Care Model are support for self-manage-
ment, appropriate delivery system design, decision support
methods, and clinical information systems.Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201Findings
Health in all policies
A comprehensive policy response to the growing challenge of
T2DM will require action at two levels. The first is action at the
societal or community level, to create environments that are less
obesogenic. The second is action at the individual level, to identi-
fy and intervene in those at risk.
The marked increase in prevalence of T2DM has mirrored the
epidemic of its major modifiable risk factor – obesity. Large scale
societal changes, and in particular the industrialisation of food
production and the growth in motorised transport, both coupled
with rising incomes, have contributed to a situation in which
people are consuming more calories than they expend, and sub-
sequently gaining weight at an alarming rate. This phenomenon
is seen in its most extreme form in populations that have evolved
over generations in settings at risk of periodic famine, who now
have access to secure and plentiful food supplies and where mo-
torised transport has brought about greatly reduced physical ac-
tivity [225]. This has led researchers to coin the term “obesogenic
environment” [295]. This is defined as “the sum of influences that
the surrounding opportunities or conditions of life have on pro-
moting obesity in individuals or populations” [296]. Thus the in-
creasing prevalence of T2DM has its origins in policies that lie far
outside the health sector. These have recently been reviewed
elsewhere [287], but in brief, obesity is correlated with both ob-
jective measures of the environment, such as “walkability” [297]
and urban sprawl [298] or the structure of the retail food market
[299] as well as how individuals perceive the environment in
which they live (for example, fear of violence as a deterrent to
physical activity) [300]. Many of these factors are modifiable, for
example by incorporating health considerations into urban plan-
ning [262] or fiscal or legislative changes affecting food market-
ing (such as advertising bans or taxes on “junk” foods [233]).
Consequently, no matter how intensive they are, individualised
interventions within the health sector can only begin to over-
come the pervasive forces arising from the environments within
which people work, as recognised by the IDF [172] and the Amer-
ican Heart Association (AHA) [301]. Similarly, a key element of
the European Unionʼs public health strategy is Health in All Poli-
cies [302]. However, while there is a large volume of evidence
correlating characteristics of the environment with levels of obe-
sity, and thus T2DM, there are no population-based intervention
studies (for example to change the built environment or retail
food sector) that have been shown to reduce obesity. This is un-
surprising given the complexity and scale of such potential inter-
ventions. However, on the basis of the clearly demonstrated asso-
ciation between the environment and obesity, we recommend
that any individualised model of care for diabetes prevention is
accompanied by other policy responses to address obesity preva-
lence in the population. A
The economic aspects of diabetes prevention strategies
Using data from 2001 and 2002, the average annual cost of health
care in Italy for T2DM were estimated to be 1910 €/patient, with
52% of costs accounted for by medication, 28% by hospitalisation,
and 11% by diagnostic procedures [303] (2).
An earlier Swedish study calculated the annual direct and indi-
rect costs of diabetes per person to be approximately 6338 €/year.
28% of the costs were for healthcare, 41% for lost productivity
and 31% fell on the municipality and relatives [304]. The recent
IDF Diabetes Atlas [305] estimates that, in 2010, USD 105.5 billion
will be spent on healthcare for diabetes in Europe, equating to a0; 42 (Suppl. 1): S3–S36
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l.mean expenditure of USD 2046 per person with diabetes in the
region [306]. Evidently, the cost is high, emphasising the impor-
tance of identifying cost-effective strategies for prevention.
The DPP group evaluated the progression of disease, costs and
quality of life of their own program using a Markov simulation
model. They estimated that, compared with placebo, the lifestyle
intervention delayed the onset of T2DM by 11 years and de-
creased the absolute incidence by 20%. This translated into a cost
per QALY of approximately 1100 US$; or $ 8800 from a societal
perspective; and the intervention was cost-effective across all
age groups. Further, in a sensitivity analysis, cost-effectiveness
improved.
However, the DPP groupʼs analysis was later challenged by inde-
pendent researchers who found the cost-effectiveness to bemore
modest: concluding that “lifestyle modification… should be rec-
ommended to all high-risk people.” but that the DPPmay be, “too
expensive for health plans or a national program to implement”
and suggested that lower cost methods would be needed for “real
world” delivery [307] (2).
One study examined cost-effectiveness in a European context,
modelling the application of the intervention used in the DPS to
a hypothetical Swedish population of 60 year olds [308]. It as-
sumed that those at risk, on the basis of IGT, had already been
identified (so a more comprehensive evaluation would need to
incorporate these costs). It took a societal perspective and re-
ported a cost per QALY of 2363 €.
In a separate study, a group in the UK conducted a cost-effective-
ness analysis of: screening for T2DM and IGT and then imple-
menting lifestyle interventions in those found to have IGT [309]
(2). They used a hybrid decision tree/Markov model to simulate
the long term (50 year time horizon) effects of the strategy, both
in terms of clinical and cost-effectiveness outcomes. For each
QALY gained, the estimated cost of the strategy was 6242 £
(7802 €). They found that, given a willingness-to-pay threshold
of 20000 £ (25000 €), the probability of the intervention being
cost-effective was 93% and so concluded that, in a population
aged 45 at above-average risk, the strategy seemed to be cost ef-
fective.
However, a quite different conclusion emerged from a recent
meta-analysis [310] (2+). This noted that most of the available
evidence came from research settings, among high-risk popula-
tions and that, despite encouraging evidence of effectiveness, so
far the economic case for a widespread lifestyle or drug interven-
tion to prevent development of T2DM has not been made.
Adapting a model of care to the circumstances of
each country
In considering which model of care to adopt, it is necessary to
take account of the tremendous diversity of health care systems
across Europe. There is a need for flexibility, with the model
adopted being tailored to the circumstances of individual coun-
tries.
Ten responses to the survey among IMAGE partners conducted
for this work package were obtained, from Bulgaria, Finland,
Greece, Latvia, The Netherlands, Poland, Spain, Switzerland,
Ukraine and the United Kingdom. The responses, along with
those to the IMAGE “Analyses of T2DM Prevention Programmes
at national level” questionnaire, identify very fewexamples of ex-
isting national diabetes (or obesity) prevention programs.
The Finnish DPS model, which has attracted moderate overall
support, is viewed as facing several obstacles, mainly in gaining
financial support, although there are a variety of possible sourcesPaulweber B et al. IMAGE-Gof funding, including pharmaceutical companies, health insur-
ance agencies and local and regional authorities, as well as na-
tional governments. In terms of settings, there was most support
for primary health care, with university hospitals and endocri-
nologists also mentioned. There were few precedents for the de-
livery of such a program in the patientʼs home.
Two examples of potentially national level programmes were
identified. The Krakow (Poland) “City” project for the prevention
of CVD and T2DM, which commenced in 2002, is described as
being very similar to the DPS model, with screening based on
the FINDRISK and simple biochemical indices, while those at risk
are offered lifestyle intervention in the form of individual consul-
tations. Since 2005 Poland has also participated in the DE-PLAN
project and there is local enthusiasm for scaling this up to nation-
al level.
In Finland, FIN‑D2D, an implementation project (in the primary
health care setting) of the Finnish national program for the pre-
vention of T2DM, ran from 2003 to 2007 [274]. It was conducted
in 5 hospital districts – covering a total population of 1.5 million.
Subjects at high risk (identified using the FINDRISC) were offered
lifestyle modification, which although drawn directly from the
DPS seemed to be somewhat more flexible in terms of its ap-
proach. There were individual, self-acting and group interven-
tions. At enrolment, subjects underwent a global risk assessment
including a questionnaire; and then, together with their health
professional, agreed on the level of intervention required. Fur-
ther, there was flexibility as to the setting: interventions could
also be implemented outside the health care system by private
or third sector organisations. At the time of writing the evalua-
tion of FIN‑D2D is not yet published but will be extremely impor-
tant as it is one of the first projects to actually implement lifestyle
interventions to prevent diabetes in the primary care setting.
Similarly, the results of the “Diabetes in Europe-Prevention using
Lifestyle, Physical Activity and Nutritional Intervention Plan”
(DE-Plan), which involved 25 institutions from 17 European
countries, will be invaluable. The DE-Plan project is testing mod-
els of lifestyle modification intervention in individuals at high
risk of T2DM. Since the programmes are being implemented in
existing health care systems, they will provide important evalua-
tions of the cost-effectiveness and feasibility of the models used
[239].
Recommendations
A Any model of care for diabetes prevention should be accompa-
nied by other policy responses to address the determinants of
obesity in a population.
D Anymodel of caremust be able to be adapted to the specifics of
each health care system. From the evidence available to date,
FIN‑D2D appears to provide themost flexible approach. The eval-
uations of FIN‑D2D, DE-PLAN and other programs such as the
Dutch “Roadmap”will be invaluable in providing evidence for fu-
ture recommendations on model of cares. The cost-effectiveness
of “real world” T2DM prevention programs has not yet been
clearly established.Recommendations for Economic Evaluation of
T2DM Prevention Strategies
!
Effective interventions to prevent T2DM diabetes, to treat its
symptoms and delay its complications will reduce the burden of
disease to society and to patients, but require new resources souideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
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l.there is a need to analyze the cost-effectiveness of these inter-
ventions.
A The recommended perspective of economic evaluation is a
large societal perspective including: payerʼs (state and local gov-
ernments, health insurance companies), providerʼs and partici-
pantʼs perspectives of analysis [311,312] (1++), [307,313] (2++).
A The economic costs of the intervention, not financial costs
have to be assessed. All resources used, not only paid for, should
be considered.
A The ingredient approach for costs analysis is recommended
which consists of the following steps: (i) measurement of all re-
sources used by resource category (e.g. personnel, materials &
supplies, laboratory tests, equipment etc.), (ii) eliciting unit costs
(prices) of resources used (for the year of evaluation) and (iii)
multiplying quantity of resources used by their prices. The ingre-
dients approach allows comparability between different inter-
vention settings. The evaluation for another year can be easily
undertaken using revised prices of the resources used.
A It should be ensured that the time of personnel allocated to the
intervention is netted out from the remaining activities.
D Where exact measurement of costs such as office materials,
utilities, office space, computer etc. is difficult, the estimated
standard values of these costs per person-month of personnel
time involved can be applied.
B To support future planning of the necessary resources for inter-
vention, the costs should be assessed for two periods: (i) start-up
(pre-implementation phase of the programme, costs spent once),
(ii) post start-up (actual program running) [239,311,314], and for
two levels: (i) management level (costs by health care provider
and authorities involved in planning, organizing, continuous
training of the intervention managers, monitoring and supervi-
sion of the intervention) and (ii) participant level (all costs at the
individual level of delivery of the intervention).
A Two type of costs are to be analysed: (i) direct and (ii) produc-
tivity (indirect) costs. Direct medical costs comprise costs of
identifying high-risk groups, laboratory testing, implementing
and maintaining the intervention, costs of care incurred by the
intervention that are captured by costs of medical care outside
the analysed intervention. Direct non-medical costs include out-
of-pocket payments (e.g. traveling) and purchases, costs of
change of food due to the intervention, as well as value of leisure
time physical activities. It is recommended to estimate the value
of time spent on intervention by the participant using the aver-
age hourly wage in this country in the year of evaluation. Indirect
costs represent the value of production lost due to absence from
work or usual activity resulting from the intervention as well as
present value of future productivity lost due to premature death
either caused or averted by intervention. The human capital ap-
proach is recommended, applying the average annual wage and
unemployment rate of the country in the year of evaluation.
A Three groups of effects of the intervention are to be analysed:
(i) benefits achieved, measured in monetary units; (ii) effects
measured in specific units such as number of cases of T2DM
avoided; (iii) outcomes measured in time gained, adjusted for
quality of life – Quality Adjusted Life Years (QALYs) [315]. The
weights are then aggregated across time periods. The costs asso-
ciated with the added years of life can be excluded from analyses
[316] (2++).
B We recommend excluding from the analysis the costs associ-
ated with longer life achieved with intervention.
A Present the cost-effectiveness ratios for strategies applied. Pro-
vide an incremental cost-effectiveness analysis, comparing costsPaulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201and effects with lack of intervention or with current standard of
practice.
A In order to estimate the full economic impact of the interven-
tion, the lifetime health and economic consequences of prevent-
ing T2DM (progression of disease, costs and quality of life) should
be quantified. The modeling approach is recommended when di-
rect primary or secondary empirical evaluation is not possible
[198,307,315,317,318].
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l.Oral Glucose Tolerance Test (OGTT)
!
The oral glucose tolerance test (OGTT) is recommended by the
WHO for diagnosis of T2DM.
Preparation and cautions
The OGTT should be performed in the morning, after at least
three days of unrestricted carbohydrate intake (more than 150 g
of carbohydrate daily). The test should not be done during an
acute illness, as the results may not reflect the patientʼs glucose
metabolism when healthy. A full test dose of glucose for adults
should not be given to a person weighing less than 43 kg, due to
the fact excessive amount of glucose may produce a false positive
result.
The OGTT procedure
The test should be implemented after an overnight fast of 10 to
16 hours (water is allowed). Smoking or physical activity is not
permitted during the test. Usually the OGTT is scheduled to begin
in the morning (7–9 am) as glucose tolerance exhibits a diurnal
rhythm with a significant decrease in the afternoon. At baseline,
the blood sample for glucose determination is taken. The patient
is then given a glucose solution to drink. The standard dose is 75 g
of glucose in 250–300ml of water. It should be ingested within 5
minutes. For children, the test load should be 1.75 g per kg of
body weight, up to a maximum of 75 g of glucose, The next blood
sample is collected at 120min after the glucose load.
Plasma glucose measurement in blood samples
The processing of the samples after collection is important to en-
sure accurate measurement of plasma glucose. This requires rap-
id separation of the plasma after collection. Laboratory measure-
ments rely upon the use of separated plasma and only immediate
separation can prevent the lowering of the glucose in the sample.
Only if the plasma separation is completely impossible to be done
immediately upon collection, glycolysis inhibitors, e.g. sodium
fluoride (6mg per ml of the whole blood) can be used. Rapid
cooling of the sample may also be helpful in reducing the loss of
glucose if the plasma cannot be immediately separated. In this
case, the sample should be placed immediately after collection
into ice-water but the plasma separation should occur within 30
minutes. The plasma should be frozen until the glucose concen-
tration can be measured.
International Federation of Clinical Chemistry (IFCC) recom-
mended that all glucose measuring devices report the results in
plasma values. The reason for this recommendation is the fact
that plasma glucose values are approximately 11% higher than
the values of whole blood glucose measured in the same sample.
Moreover, WHO recommendation is that venous plasma glucose
should be the standard method for measuring and reporting.
However, it should be noted if one converts from venous to capil-
lary plasma glucose the conversion is different in the case of fast-
ing or post-load glucose values. Fasting values for venous and
capillary plasma glucose are identical, while the conversion is
necessary only for post-load glucose.Paulweber B et al. IMAGE-GMethods and Procedures
!
Methods
The IMAGE project is described in detail on its website (http://
www.image-project.eu/). Briefly, the development of this guide-
line followed a pre-defined step-wise procedure addressing:
(i) Stakeholder involvement: the IMAGE guideline development
group included diabetes specialists, public health and primary
care health professionals, behavioural and social scientists, epi-
demiologists, patientsʼ organisations, health professional organi-
sations, multidisciplinary, health economists, and health promo-
tion, health policy and health services researchers (for details see
Acknowledgements and website). All stakeholders were con-
sulted at numerous stages including the design of the project,
definition of the scope and purpose, identification of relevant
evidence and developing and refining drafts and final versions
of the guideline.
(ii) Scope and purpose: the overall objectives of the guideline
were developed through consultation with all stakeholders by
email, teleconference and a 2-day symposium. By this process,
the clinical questions and target population covered by the
guideline were defined and separate working groups established
to synthesise the evidence under the following headings: defini-
tions of risk and target population; screening tools, diagnosis and
detection; prevention of T2DM and its comorbidities; supporting
change in lifestyle behavior for adults at risk of T2DM; models of
care and economic aspects of T2DM prevention; and recommen-
dations for economic evaluation of T2DM prevention strategies.
(iii) Evidence identification and review: systematic methods
were used to identify relevant evidence using defined search
strategies appropriate to the specific topic (see Methodology sec-
tions), use of multiple databases, follow up of cited references,
and consultation with experts in the field. Criteria for selecting
and evaluating the quality of the evidence were based only on
publications in peer-reviewed scientific journals and are de-
scribed in detail (see Methodology sections). Throughout the
guideline, SIGN guidance was used to define the criteria for levels
(quality) of evidence and grades of the resulting recommenda-
tion, which are provided at the end of each chapter. Health bene-
fits, side effects, and risks were considered in formulating these
recommendations whichwere linked to the supporting evidence.
Prior to publication, experts externally reviewed the guideline. A
procedure for updating the guideline is to be defined.
(iv) Clarity and presentation: the recommendations were re-
viewed to ensure they are specific and unambiguous. Contextu-
ally specific issues arising in each participating European country
were discussed to minimise any misunderstanding or misinter-
pretation. Different options for management are clearly present-
ed and the key recommendations are easily identifiable. The
guideline is supported by tools and materials for its application
(see website).
(iv) Implementation and dissemination: Potential organization-
al barriers to applying the recommendations were discussed and
addressed where possible. The potential cost implications of ap-
plying the recommendations were considered (recognising thatuideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
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of inputs and unit costs) and the guideline presents key review
criteria for monitoring and/or audit purposes. A plan for dissem-
inating the guideline to relevant professional groups and persons
with increased diabetes risk is in development.
(v) Editorial independence: The guideline is editorially indepen-
dent from the funding body. Conflicts of interest of guideline de-
velopment members have been recorded in the Acknowledge-
ments.
Procedures
At the initial meeting of the guideline development group (Mu-
nich, November 2007), the partners discussed the overall project
strategies and, based on their specific expertise, assigned them-
selves to the different working groups. Working group leaders
were decided by consensus within each group. Communication
occurredwithin and across theworking groups by email, intranet
and face-to-face meetings. During a 2-day meeting (Vienna,
March 2008), the available information was pre-screened, exclu-
sion and inclusion criteria defined, methodology for evidence
identification, grading and recommendation development was
further discussed and additional partners allocated to the work-
ing groups. Drafts on specific topics were circulated by email and
discussed at a further 1-day meeting (Helsinki, June 2008) andPaulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201across the WPs at a further 2-day meeting (Mallorca, November
2008). In January 2009, the completed drafts were disseminated
as a first version of the completed guideline to all stakeholders
via email and intranet. After consensus was reached on the con-
tents, the guideline was shortened and edited. Consensus on the
final version of the guideline, authors list and publication strat-
egies was achieved during the final 2-day IMAGE meeting (Lis-
bon, October 2009).
Strengths and limitations
The evidence-based guideline focuses primarily on the European
environment. It does not address specific requirements for ethnic
minority groups and people with different social and cultural
backgrounds. Although the working groups took note of the spe-
cific need for prevention of obesity and diabetes in children with
metabolic risk factors, it was determined that this laid outside
the scope of this guideline. Although many of the interventions
identified can be expected to have similar effects in children, the
metabolic, psychosocial, behavioural and medical requirements
may be different. Despite these limitations, the IMAGE guideline
applies to more than 80% of people with increased metabolic risk
in Europe. Further work is necessary to extend the scope of the
guideline and to address the needs of children and specific ethnic
groups.0; 42 (Suppl. 1): S3–S36
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